

Kongeriget Danmark


Patent application No.: PA 2003 00862
Date of filing: 10 June 2003
Applicant: ACE BioSciences A/S
(Name and address) Unsbjergvej 2a
DK-5220 Odense SØ
Denmark

Title: Extracellular Aspergillus polypeptides

IPC: -

This is to certify that the attached documents are exact copies of the above mentioned patent application as originally filed.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)



Patent- og Varemærkestyrelsen
Økonomi- og Erhvervsministeriet

30 June 2004

Pia Høybye-Olsen

10 JUNI 2003

Modtaget

Extracellular *Aspergillus* polypeptides

5 All patent and non-patent references cited in this application are hereby incorporated by reference in their entirety.

Field of the invention

10 The present invention relates to extracellular polypeptides of *Aspergillus fumigatus*, to fragments of these polypeptides, to compositions comprising such polypeptides and fragments and to exposed domains and epitopes of these polypeptides. The invention also relates to the use of these polypeptides and fragments for immunisation and for production of antibodies, and to antibodies that specifically recognise and bind the polypeptides. Furthermore, the invention relates to methods of identifying binding partners and inhibitors, and to methods of diagnosing
15 *Aspergillus* infections.

Background of the invention

20 The rise of diseases that attack the immune system, such as AIDS, and medical treatments that depress the immune system, such as cancer chemotherapy or organ transplantation, have resulted in an increase in the death rate caused by fungal infections. Since the mid-1980's, fungal pathogens have begun to rival their bacterial counterparts in many different medical settings. Species of the *Aspergillus* family account for a substantial number of these fungal infections and in particular *Aspergillus fumigatus* has emerged world-wide as a frequent cause of nosocomial
25 infection in virtually every major medical centre. For almost 30 years, amphotericin B was the only drug approved for treating serious fungal infections despite significant kidney toxicity. Azoles were introduced in the 1980s for treating the most common fungal pathogen, *Candida albicans*, which is responsible for approximately 50% of fungal infections. Widespread use of azoles encouraged the development of
30 resistant strains to this drug. Unfortunately, most currently marketed azoles are largely ineffective against the more severe forms of fungal disease, such as infections caused by *Aspergillus*. The increase in drug-resistant strains of fungal pathogens further underscores the need for new antimicrobial treatments.

Aspergillus fumigatus is a saprophytic fungus found ubiquitously in the environment, particularly in soil and in water and may be readily found in very large numbers in hay, grain and decaying organic matter. *Aspergillus fumigatus* plays an essential role in recycling environmental carbon and nitrogen. Reservoirs in hospitals and other institutions include unfiltered air, ventilation systems, contaminated dust during construction work, carpeting, food, ornamental plants and water and water supply systems. It is generally believed that aspergillosis occurs as a consequence of the exogenous acquisition of spores; they are small enough ($2.5\text{--}3.0\ \mu\text{m}$) to reach the alveoli upon inhalation and hardy enough to survive for prolonged periods in fomites. It remains unclear what the size of the infectious inoculum needs to be, although this probably depends upon the immunological status of the host. There are around 600 recognised species, but only a small number have been identified as pathogenic. Among these *A. fumigatus* which causes over 80% of human infections caused by *Aspergillus* species. *A. fumigatus* is an opportunistic pathogen and normal individuals are not susceptible to disease except after inhalation of large quantities of spores. *Aspergillus* can cause illness in at least three ways: an allergic reaction in asthmatics (allergic aspergillosis); a colonization in scarred lung tissue (aspergilloma); and an invasive infection with pneumonia which can affect the heart, lungs, brain and kidneys (invasive aspergillosis).

Allergic aspergillosis

In the first type of aspergillosis illness, people with allergic asthma or genetic predisposition may develop this form of asthma upon becoming sensitised to *Aspergillus* species. Asthmatics may find their asthmatic condition aggravated upon exposure to *A. fumigatus*. Some people develop allergic bronchopulmonary aspergillosis (ABPA), a condition in which *Aspergillus* spores germinate and the resultant mycelial growth can potentially block the bronchi. Patients may cough up small, brown plugs of mycelia. There is no invasion of tissue. However, the patient may suffer lung fibrosis and may, over time, become more susceptible to other lung diseases. ABPA is currently the most severe allergic pulmonary complication caused by *Aspergillus* species. It occurs in patients suffering from atopic asthma or cystic fibrosis. Another disease entity, related to ABPA only because it is immune-mediated, hypersensitivity pneumonitis (also called extrinsic allergic alveolitis) is often associated with repeated exposure to an identified -- often occupational -- source of high levels of antigen.

Aspergilloma

Aspergilloma, commonly referred to as "fungus ball," occurs in pre-existing pulmonary cavities that were caused by tuberculosis, sarcoidosis, or other bullous lung disorders and in chronically obstructed paranasal sinuses.

Invasive aspergillosis (IA)

Invasive aspergillosis (IA) is seen in people whose normal immune systems are compromised by other serious diseases such as leukaemia, lymphoma, carcinoma, tuberculosis, emphysema, diabetes, HIV/AIDS or by use of immunosuppressive drugs (often used in connection with organ or bone marrow transplant operations); or by large doses of corticosteroids. In IA, there is an actual invasion of lung tissue or skin. Infection can also occur in many organs or tissues, e.g. heart, liver, eye, nose, ear and skeletal muscle. Pathologically invasive infections show clear invasion of the underlying tissue, eventually leading to bloodstream dissemination or contiguous spread to adjacent structures. The prognosis for IA is serious illness and death.

A fourfold increase in IA has been observed in the last 12 years. In 1992, IA was responsible for approximately 30% of fungal infections in patients dying of cancer, and it is estimated that IA occurs in 10 to 25% of all leukaemia patients, in whom the mortality rate is 80 to 90%, even when treated. The average incidence of IA is estimated to be 5 to 25% in patients with acute leukaemia, 5 to 10% after allogeneic bone marrow transplantation (BMT), and 0.5 to 5% after cytotoxic treatment of blood diseases or autologous BMT and solid-organ transplantation. IA which follows solid-organ transplantation is most common in heart-lung transplant patients (19 to 26%) and is found, in decreasing order, in liver, heart, lung, and kidney recipients (1 to 10%) (Patel and Paya, 1997, Clin. Microbiol. Rev. 10: 86-124). IA also occurs in patients with nonhematogenous underlying conditions; it is increasingly reported in AIDS patients (1 to 12%) (Denning et al., 1991, N. Engl. J. Med. 324: 654-662) and is also a common infectious complication of chronic granulomatous disease (25 to 40%). Four types of IA have been described (Denning, 1998, Clin. Infect. Dis. 26: 781-805): (i) acute or chronic pulmonary aspergillosis, the most common form of IA; (ii) tracheobronchitis and obstructive bronchial disease with various degrees of invasion of the mucosa and cartilage as well as pseudomembrane formation, seen

predominantly in AIDS patients; (iii) acute invasive rhinosinusitis; and (iv) disseminated disease commonly involving the brain (10 to 40% in BMT patients) and other organs (for example, the skin, kidneys, heart, and eyes).

5 Diagnosis of *Aspergillus* infections

Unlike bacterial infections, cultures from blood or cerebrospinal fluid and other sterile body fluids - are rarely positive for *Aspergillus* species, even in patients with endocarditis and disseminated disease. Given the ubiquitous nature of the spores, recovering *Aspergillus* from cultures of the respiratory tract does not discriminate between genuine infection, colonization or contamination. A number of clinical findings may trigger a diagnosis of invasive aspergillosis, such as neutropenic fever not responding to broad-spectrum antibiotics, the development of new pulmonary infiltrates on chest X-ray and the presence of clinical signs suggestive of invasive mycosis (e.g. pleuritic chest pain, hemoptysis, etc.). Unfortunately, most of these triggers have low predictive value. Therefore, the only way to reach a precise and early diagnosis is to make intense efforts to collect specimens for culture and histopathological examination (by biopsy or needle aspiration). However, this gold standard approach involves aggressive procedures (open lung biopsy, brain biopsy, etc.) that are often precluded by cytopenia or by the critical condition of the patient. Hence, definitive diagnosis is infrequently made before fungal proliferation becomes overwhelming and therapy may no longer be successful.

The detection of anti-*Aspergillus* antibodies has no place in the diagnosis of aspergillosis in neutropenic patients and hematopoietic stem cell transplant recipients because these populations are not capable of mounting an adequate antibody response. Diagnostic tools used at the moment are galactomannan detection (a major cell wall constituent released during growth), high-resolution pulmonary CT-scanning and detection of aspergillar DNA. Obtaining both high sensitivity and high selectivity remains a problem, and there is a need for novel reliable diagnostic markers.

30 Currently available anti-*Aspergillus* agents

The antifungal armamentarium that is currently available for the treatment of invasive aspergillosis is limited in number. It includes:

- 35 1. The polyene macrolide, amphotericin-B and its lipid-based formulations;

2. the triazole, itraconazole;
3. the fluorinated pyrimidine, 5-fluorocytosine; and
4. the allylamine, terbinafine.

5 The lack of a highly selective fungal target, not present in other eukaryotic cells, has for a long time precluded the development of new agents. With the exception of 5-fluorocytosine, all available agents act by interfering with the structural or functional integrity of the fungal plasma membrane, either by physical disruption or by blocking the biosynthesis of membrane sterols. This strategy remains far from ideal since the non-selective nature of the therapeutic target results in concomitant cross-inhibition
10 (or toxicity) in mammalian cells.

Treatment with antifungal drugs such as amphotericin-B and/or itraconazole involves many difficulties. Amphotericin-B, flucytosine and itraconazole are associated with low success rates and are hampered by serious infusion- or drug-related toxicity, by hazardous drug-drug interactions, by pharmacokinetic problems
15 and by the development of resistance. Amphotericin-B has to be given by vein in large doses. In some patients the treatment can damage kidney and other organs. The overall success rate of Amphotericin-B therapy for IA is 34%. In addition, most IA cases occur in spite of empirical administration of Amphotericin-B in response to a fever unresponsive to antibacterial agents. Itraconazole is generally given orally
20 (also in large doses, e.g. at least 400 mg daily) and has been used for many years as a treatment, but even so, mortality is still as high as 85%.

Vaccination

25 Vaccination may be another approach for combating *Aspergillus* infections. As explained above, IA is a severe problem for immunocompromised patients and especially in neutropenic patients, who have lost all their acquired immune response and are virtually without memory, *Aspergillus* infection is lethal in most cases. It seems that vaccination of these patients prior to immune suppression would not be a viable
30 strategy. However, vaccination of a bone marrow donor could assist in the clearance of infection post donation. Also passive immunisation with immunoglobulins may be an option. Until now there have been no extensive preclinical and/or clinical data available concerning the efficacy of specific immunoglobulins. However, there are reports from invasive *Aspergillosis* studies in mice that show that active vaccina-

tion has influence on their mortality rate (Ito and Lyons (2002) J. Infect. Dis. 186, 869-871).

Targets

5 As *A. fumigatus* is becoming a major fungal pathogen of humans there is an urgent need for identification of suitable biochemical targets in *A. fumigatus* and for the discovery and development of new effective antifungal agents active against such biochemical targets. Recently, the *A. fumigatus* genome was analysed by random
10 shotgun DNA sequencing. By sequence comparison with *Candida albicans* genes known to be essential for survival, a large number of potentially essential *A. fumigatus* genes was identified (WO 02/086090). Such genes may potentially be interesting drug targets, but information on structure, function or cellular localisation of most of the encoded gene products is not yet available.

15 **Summary of the Invention**

The present application relates to extracellular polypeptides of *A. fumigatus*. In the context of this application, an 'extracellular polypeptide' is defined as a polypeptide which is entirely or partially (i.e. part of the polypeptide chain or part of the population of polypeptide molecules) localised outside the plasma membrane of a
20 fungal cell. Thus, extracellular polypeptides include plasma-membrane polypeptides which have extracellular parts, cell-wall polypeptides, periplasmic polypeptides, secreted polypeptides and all other polypeptides that are fully or partially exposed to or released into the space outside the plasma membrane. Extracellular polypeptides furthermore include all polypeptides or polypeptide fragments that can be found in
25 cell-wall, cell-surface-exposed and diffusate fractions isolated as described herein.

Extracellular polypeptides are attractive targets for antifungal therapy and/or diagnosis since the exposure of such polypeptides to the extracellular space means that compounds that interact with these peptides (e.g. compounds used to prevent,
30 treat or diagnose fungal infections) often do not need to pass through the plasma membrane to be effective. This is a considerable advantage as the plasma membrane constitutes a major barrier for most types of compounds.

Extracellular localisation of a fungal protein can usually not be predicted from its
35 amino-acid sequence. The presence of a signal sequence mediating entrance of

protein into the secretory pathway can be predicted with a high degree of certainty, but many proteins carrying such sequences remain intracellular, in compartments such as the endoplasmic reticulum, the Golgi complex, endosomes and lysosomes. Very little is known about sorting signals in *A. fumigatus*.

5

In principle, localisation of *A. fumigatus* proteins could be inferred from a known localisation of homologous proteins in other fungi, such as *Saccharomyces cerevisiae* or the pathogenic yeast *Candida albicans*, which are much better characterised than *A. fumigatus*. However, in practice, such predictions are highly uncertain. A recently performed genetic screening for putative exported *C. albicans* proteins identified a number of such proteins whose closest homologue was an intracellular protein (Monteoliva et al. (2002) Eukaryotic Cell 1, 514-525). Thus, even with the genome sequence of *A. fumigatus* available, it is not easy to predict which polypeptides can be found extracellularly.

15

The inventors have isolated and analysed cell-wall-, cell-surface-exposed- and diffusate fractions of *A. fumigatus* and thus determined extracellular localisation of the following six polypeptides:

20

1. The polypeptide set forth in SEQ ID NO:1. This polypeptide has not previously been detected in *A. fumigatus*, as it was only previously proposed as a putative gene product on the basis of a nucleotide sequence. It is herein proposed to name this polypeptide Cssl, for Conidial Surface and Secreted protein I.

25

2. Hydrophobin (SEQ ID NO:2). Previously described in Parta et al. (1994) Infect. Immun. 62, 4389-4395.

3. GAPDH-B, glyceraldehyde 3-phosphate dehydrogenase (SEQ ID NO:3). A 172 amino-acid fragment of this sequence has been described in the NCBI database under accession number AAL25819 (SEQ ID NO:35). However, the full-length polypeptide has not been described previously.

30

4. enolase (SEQ ID NO: 4). Described in the NCBI database under accession number AAK49451.

5. catalase B (SEQ ID NO:5). Described in the NCBI database under accession number AAB71223 and in Calera et al. (1997) Infect. Immun. 65, 4718-4724.

35

6. catalase A (SEQ ID NO:6). Described in the NCBI database under accession number U87630.

For several of these polypeptides, no localisation was known previously. For all polypeptides, novel polypeptide fragments that are useful in prevention, therapy or diagnosis of *Aspergillus* infections were identified by the inventors. Several of these fragments are relatively accessible from the extracellular space or released into it.

In a first main aspect, the invention relates to the polypeptide set forth in SEQ ID NO:3 and variants and fragments thereof, with the proviso that the fragment does not consist of the sequence set forth in SEQ ID NO:35.

In another main aspect, the invention relates to polypeptide fragments which are derived from the six polypeptides set forth in SEQ ID NOs: 1-6, and comprise one or more amino-acid residues from the sequences set forth in SEQ ID NOs:7-34. The invention also relates to variants of these polypeptide fragments.

The invention also relates to exposed domains and epitopes which are comprised within or comprise part of the polypeptides or polypeptide fragments of the invention.

Furthermore, the invention relates to compositions comprising one or more extracellular *Aspergillus* polypeptides or polypeptide fragments of the invention.

The techniques that were used by the inventors in the identification of polypeptides in the different cell-wall-, cell-surface-exposed and/or diffusate fractions favour identification of highly expressed proteins. Thus, the six polypeptides that were identified are relatively abundant. This, added to the determination that they are exposed to the extracellular environment of the cell, make them highly suitable as biochemical targets or diagnostic markers. Thus, the identification of these polypeptides in these fractions by the inventors formed the basis for the development of methods aimed at prevention, treatment and/or diagnosis of *Aspergillus* infections.

Accordingly, in a main aspect, the invention relates to use of polypeptides or fragments of the invention for generating a medicament. Preferably, a medicament that can be used for the immunisation or vaccination of a mammal, preferably a human being, preferably to generate a protective immune response.

Furthermore, in another main aspect, the invention relates to methods of raising antibodies against these polypeptides or fragments thereof in non-human mammals. The invention also relates to antibodies specifically recognising and binding one of the polypeptides set forth in SEQ ID NOs:1-6 and/or polypeptide fragments of the invention. Use of such antibodies for making a medicament for treatment or prevention of infection with *Aspergillus* is also an aspect of the invention.

Furthermore, the invention relates to methods for screening for binding partners and/or inhibitors of these extracellular polypeptides, to methods for screening for antifungal agents and to methods aimed at diagnosing *Aspergillus* infections.

Description of Drawings

Table 1: Identification of peptides in AfC fractions.

Figure 1: The predicted protein sequences of Cssl (A), hydrophobin (B), GAPDH-B (C), enolase (D), catalase B (E), and catalase A (F).

Table 2: Biochemical characteristics of Cssl

Figure 2: The predicted antigenicity indices of Cssl (A) and hydrophobin (B) residues.

Figure 3: Alignment of the predicted protein sequences for GAPDH-A (AfA), GAPDH-B (AfB), and GAPDH-C (AfC).

Detailed description of the invention

Definitions

A 'fragment' or 'polypeptide fragment' is defined as a non-full-length part of a polypeptide. The length of fragments may vary from 2 amino-acid residues to the full-length polypeptide minus one amino-acid residue. Preferably, fragments are less than 100 amino acids, such as less than 50 amino acids, e.g. less than 40 amino acids, such as less than 30 amino acids, e.g. less than 25 amino acids, such as less than 20 amino acids in length. Thus, for example fragments can be 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19 or 20 amino acids in length. Expressed in another way, a fragment consists of a part of an amino-acid sequence which is less than 100% in length as compared to the full-length polypeptide.

Preferably the length of the fragment is less than 50%, such as less than 25%, such as less than 10% of the length of the full-length polypeptide.

5 'Variants' of a given polypeptide or fragment are polypeptides or peptides that display a certain degree of sequence identity to said polypeptide or fragment. Variants preferably have at least 75% sequence identity, for example at least 80% sequence identity, such as at least 85% sequence identity, for example at least 90% sequence identity, such as at least 91% sequence identity, such as at least 92% sequence identity, for example at least 93% sequence identity, such as at least 94% sequence identity, for example at least 95% sequence identity, such as at least 96% sequence identity, for example at least 97% sequence identity, such as at least 98% sequence identity, for example 99% sequence identity with the given polypeptide or fragment. Sequence identity is determined with any of the algorithms GAP, BESTFIT, or FASTA in the Wisconsin Genetics Software Package Release 7.0, using default gap weights.

10

15

Preferred variants of a given polypeptide or fragment are variants in which all amino-acid substitutions between the variant and the given polypeptide or fragment are conservative substitutions. Conservative amino-acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine, a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino-acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

20

25

30

Variants of a polypeptide or of a fragment thereof also include forms of the polypeptide or fragment wherein one or more amino acids have been deleted or inserted. Preferably, less than 5, such as less than 4, e.g. less than 3, such as less than 2, e.g. only one amino acid has been inserted or deleted. 'Variants' of a polypeptide or of a fragment thereof also include forms of these polypeptides or

35

fragments modified by post-translational modifications of the amino-acid sequence. Also included are fusion proteins wherein the given polypeptide or fragment thereof has been fused (on the gene level or post-translationally) to another peptide or polypeptide.

5

An 'exposed domain' is defined as a part of a polypeptide that is exposed to the external environment. Secreted or released parts of polypeptides, which are not cell-associated, are examples of exposed domains. Exposed domains can also be found in polypeptides that are cell-associated. This can e.g. be determined by protease treatment as described herein in the Examples. I.e. an exposed domain of a polypeptide is a part of the polypeptide which is more accessible for proteases, such as trypsin or chymotrypsin, than other parts of the same polypeptide, and can be released from cellular association by protease treatment without disrupting the integrity of the cell. Surface exposure of a domain can also be determined using indirect immunofluorescence analysis, e.g. as described by Sanjuan et al. (1996) Microbiology 142, 2255-2262. Exposed domains of plasma-membrane-associated polypeptides are parts of such polypeptides that are located immediately adjacent to membrane-spanning regions and are located on the extracellular side of the plasma membrane. An exposed domain can be flanked on both or on only one side by a membrane-spanning region. Membrane-spanning regions can be predicted by a variety of methods, reviewed in Möller et al. (2001) Bioinformatics 17, 646-653. In a preferred embodiment, an exposed domain of a plasma-membrane-associated polypeptide is a part of a polypeptide located on the extracellular side of the plasma membrane, immediately adjacent to a membrane-spanning region (transmembrane helix) as predicted by the TMHMM program 2.0 (Krogh et al. (2001) J. Mol. Biol. 305, 567-580.

'Epitope' in this context covers any part of a polypeptide capable of being recognised by an antibody or functional equivalent thereof. Epitopes may consist of a stretch of consecutive amino-acid residues or of non-consecutive parts of a polypeptide. Typically, an epitope consists of 2-20 amino acids, such as 3-10 amino acids, preferably 3-8 amino acids, such as 3,4,5,6,7 or 8 amino acids.

'Expression vector' refers to a plasmid or phage or virus, for producing a polypeptide from a polynucleotide sequence. An expression vector comprises an expression

construct, comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and which is operably linked to the elements of (1); and (3) appropriate transcription initiation and termination sequences.

A 'binding partner' of a polypeptide refers to a molecule that can bind to said polypeptide. Such binding can be indirect, through another molecule, but is preferably direct. A binding partner can be any type of molecule, such as e.g. small hydrophobic molecules or e.g. a cellular or extracellular macromolecule, such as a protein, a carbohydrate or a nucleic acid. Preferred types of binding partners include antibodies, ligands or inhibitors.

The term 'plurality' indicates more than one, preferably more than 10.

'Secreted' in the present context refers to soluble polypeptides or fragments thereof that are not cell-associated and thus in principle diffuse freely in the surrounding medium. This includes fragments of polypeptides that are released from cellular association, for instance through proteolysis.

The term 'indicator moiety' covers a molecule or a complex of molecules that can be detected or generates a detectable signal. Preferably, the indicator moiety is an antibody or includes an antibody molecule. Thus, a preferred indicator moiety is an antibody coupled to a detectable substance. The detectable substance can in some embodiments comprise a second antibody.

'Host-derived molecule' or 'host molecule' refers to a molecule which is normally found in a host organism that can be infected with *A. fumigatus*. A host-derived molecule is preferably a host polypeptide, preferably a human polypeptide. Examples of host-derived molecules that interact with pathogenic fungi are serum albumin and transferrin, fibrinogen, complement fragment C3d, complement fragment iC3b, laminin, fibronectin, entactin, vitronectin, mannan adhesins, epithelial binding lectin-like protein, and agglutinin-like proteins.

The term 'antibodies' when used herein is intended to cover antibodies as well as functional equivalents thereof. Thus, this includes polyclonal antibodies, monoclonal antibodies (mAbs), human, humanised or chimeric antibodies, single-chain antibodies, and also Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic antibodies, hybrids comprising antibody fragments, and epitope-binding fragments of any of the these. The term also includes mixtures of monoclonal antibodies.

'Isolated' used in connection with polypeptides and polynucleotides disclosed herein refers to these having been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.

Polypeptides of the invention

Fragments of extracellular *Aspergillus* polypeptides

The analysis of three different *Aspergillus* fractions (diffusate, cell-surface-exposed and cell wall) that was performed by the inventors led to the identification of different types and numbers of fragments from the same polypeptides for each of the fractions. For example, as is described in Example 1, five Cssl peptides were identified in the cell-wall fraction while only one was identified in diffusate and cell-surface-exposed fractions. This difference may indicate structural features of the protein. Without being limited to a specific theory, a possible explanation for this is that a portion of Cssl can be cleaved from the cell wall, releasing one part of the protein into the surrounding milieu, while the remainder of the protein remains embedded in the cell wall. Similarly, although other explanations are possible, the fact that only one peptide is detected in cell-surface fractions may suggest that an area of the protein comprising that peptide is exposed while the remainder of the protein is not. Even regions of a polypeptide which are not embedded in other cellular structures such as the cell wall, may still contain parts that are more accessible than other parts. For instance, the surface of a polypeptide may be more accessible than parts of the polypeptide which are buried within a tertiary protein structure. Protease treatment may also identify such protein surface regions.

Thus, the inventors have identified protein regions of particular interest. Exposed domains are, due to their accessibility, particularly attractive targets for diagnosis or for antifungal treatment. Moreover, exposed polypeptide fragments or domains are likely to contribute to, or comprise epitopes, and thus be highly suitable for antibody recognition. For many of the applications described below, it can be advantageous to work with fragments that are larger than the ones that were identified by the inventors. This can in particular be the case for methods of finding binding partners and methods for raising antibodies, such as immunisation, which sometimes do not work well with small fragments.

In a main aspect, the invention relates to fragments of extracellular *Aspergillus* polypeptides that comprise exposed domains and/or epitopes. The invention also relates to the full-length GAPDH-B polypeptide (SEQ ID NO:3), discussed below.

Accordingly, in a main aspect, the invention relates to an *Aspergillus* polypeptide selected from the group of

fragments of SEQ ID NO:1 of less than 259 amino-acid residues in length, such as less than 200, preferably less than 150, such as less than 100, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:7,8,17,26,28,29 and/or 30 and variants of said fragments;

fragments of SEQ ID NO:2 of less than 106 amino-acid residues in length, such as less than 75, preferably less than 50, such as less than 25 residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:9,10,18 and/or 19 and variants of said fragments;

polypeptides comprising SEQ ID NO 3, fragments thereof and variants thereof, with the proviso that if the polypeptide is a fragment of SEQ ID NO:3, that this fragment is not the fragment set forth in SEQ ID NO:35;

fragments of SEQ ID NO:4 of less than 437 amino-acid residues in length, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues

of the amino-acid sequences set forth in SEQ ID NO:13,14,23,24 and/or 25 and variants of said fragments;

5 fragments of SEQ ID NO:5 of less than 727 amino-acid residues in length, e.g. less than 400, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:15,16 and/or 27 and variants of said fragments;

10 and

15 fragments of SEQ ID NO:6 of less than 748 amino-acid residues in length, e.g. less than 400, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:34 and variants of said fragments.

20 In a preferred embodiment, the above fragments comprise one or more residues of the amino-acid sequences set forth in SEQ ID NOs: 7-27. In a more preferred embodiment, the fragments comprise one or more residues of the amino-acid sequences set forth in SEQ ID NOs: 7-16. In another more preferred embodiment, the fragments comprise one or more residues of the amino-acid sequences set forth in SEQ ID NOs: 17-25 and/or SEQ ID NO:14. In yet another more preferred embodiment, the fragments comprise one or more residues of the amino-acid sequences set forth in SEQ ID NO: 18, 19, 26, and/or 27.

30 Further preferred polypeptides are fragments of SEQ ID NO:1 of less than 259 amino-acid residues in length, such as less than 200, preferably less than 150, such as less than 100, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:7,8,17,26,28,29 and/or 30, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:7, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:8, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:17, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:26, such as one or more residues of

35

the amino-acid sequences set forth in SEQ ID NO:28, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:29, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:30.

5 Further preferred polypeptides are fragments of SEQ ID NO:2 of less than 106 amino-acid residues in length, such as less than 75, preferably less than 50, such as less than 25 residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:9,10,18 and/or 19, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:9, e.g. one or more residues of
10 the amino-acid sequence set forth in SEQ ID NO:10, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:18, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:19.

15 Preferred polypeptides include fragments of SEQ ID NO:3, with the proviso that if the polypeptide is a fragment of SEQ ID NO:3, that this fragment is not the fragment set forth in SEQ ID NO:35. Preferred are fragments of SEQ ID NO:3 of less than 171 amino acids in length, such as less than 150, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID
20 NO:11,12,20,21,22,31,32 and/or 33, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:11, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:12, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:20, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:21, such as one or more residues of
25 the amino-acid sequences set forth in SEQ ID NO:22, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:31, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:32, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:33. Other preferred fragments of SEQ ID NO:3 are fragment between 173 residues and 317 residues in length,
30 comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:11,12,20,21 and/or 22 or variants of said fragments.

Further preferred polypeptides are fragments of SEQ ID NO:4 of less than 437 amino-acid residues in length, such as less than 200, preferably less than 100, such
35 as less than 75, e.g. less than 50, such as less than 25 amino-acid residues, in

length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:13,14,23,24 and/or 25, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:13, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:14, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:23, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:24, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:25.

Further preferred polypeptides are fragments of SEQ ID NO:5 of less than 727 amino-acid residues in length, e.g. less than 400, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:15,16 and/or 27, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:15, e.g. one or more residues of the amino-acid sequence set forth in SEQ ID NO:16, such as one or more residues of the amino-acid sequences set forth in SEQ ID NO:27.

Further preferred polypeptides are fragments of SEQ ID NO:6 of less than 748 amino-acid residues in length, e.g. less than 400, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:34.

Preferably, the above defined polypeptide fragments of SEQ ID NOs:1-6 comprise more than one residue of the specified amino-acid sequence, such as 2,3,4,5,6,7,8 or 9 residues of the specified amino-acid sequence. A non-limiting example of such a preferred fragment is a fragment of SEQ ID NO:1 comprising 9 residues of the amino-acid sequence set forth in SEQ ID NO:7. Most preferably, the above polypeptide fragments comprise all residues of the specified amino-acid sequence. A non-limiting example of a most preferred fragment is a fragment of SEQ ID NO:1 comprising all 16 residues of the amino-acid sequence set forth in SEQ ID NO:7.

In one embodiment, the polypeptide of the invention, preferably consists of an exposed domain, such as domains comprising an amino-acid sequence selected from the group of SEQ ID NOs: 7-34, preferably the group of SEQ ID NOs: 7-27,

more preferably the group of SEQ ID NOs:17-27 and SEQ ID NO:14, or variants thereof. An exposed domain may be determined as described above in the definition section.

5 Further preferred polypeptides consist of an epitope of a polypeptide selected from the group of SEQ ID NO: 1-6, comprising at least one amino acid from a peptide selected from the group of SEQ ID NO: 7-27, and fragments or variants of said epitope. In one preferred embodiment, the amino acid residues of the epitope are consecutive residues from the polypeptide. In another preferred embodiment, the
10 amino acid residues of the epitope are non-consecutive residues from the polypeptide. Further preferred embodiments include more than 1, such as more than 2, preferably more than 3, such as more than 4 consecutive or non-consecutive amino acids of the sequences of SEQ ID NO: 7-27. The invention also relates to use of such epitopes in any of the methods or preferred methods of the invention.

15

Fragments that consist or essentially consist of an amino-acid sequence selected from the group of SEQ ID NO: 7-34.

Preferred polypeptide of the invention are fragments of one of the polypeptides set forth in SEQ ID NO:1-6 that essentially consist of one of the fragments set forth in
20 SEQ ID NO:7-34. 'Essentially consists of' is meant to indicate that the fragment comprises a substantial part of an amino-acid sequence selected from the group of SEQ ID NO:7-34 and in addition to that contains 10 or fewer flanking residues from the polypeptide on either or both (N-terminal and/or C-terminal) sides of the smaller fragment. A 'substantial part' herein means at least 2, such as at least 5 amino acids
25 of any of the amino acid sequence set forth in SEQ ID NO:7-34. Such a fragment thus overlaps with the corresponding fragment selected from the group of SEQ ID NO:7-34. Preferably, the fragment that essentially consists of any of the amino-acid sequences set forth in SEQ ID NO:7-34 comprises the entire amino-acid sequence of that sequence. Thus, a preferred fragment of the invention is a fragment of one of
30 the polypeptides set forth in SEQ ID NO:1-6 that comprises and essentially consists of one of the fragments set forth in SEQ ID NO:7-34. Such a fragment is thus larger than the corresponding fragment selected from the group of SEQ ID NO:7-34. 'Comprises and essentially consists of' is meant to indicate that the larger fragment comprises a smaller peptide selected from the group of SEQ ID NO:7-34 and in
35 addition to that contains 10 or fewer flanking residues from the polypeptide on either

or both (N-terminal and/or C-terminal) sides of the smaller fragment. Preferably, the larger fragment contains fewer than 8, such as fewer than 6, e.g. fewer than 4, e.g. fewer than 3, such as 2 or only 1 residue on one or both sides of the smaller fragment.

5

Most preferred polypeptides of the invention are fragments selected from the group of SEQ ID NO: 7-34. Thus, such most preferred polypeptides include any of the fragments from the group of fragments set forth in SEQ ID NO:7-34, such as the fragment set forth in SEQ ID NO:7, or the fragment set forth in SEQ ID NO:8, or the fragment set forth in SEQ ID NO:9, or the fragment set forth in SEQ ID NO:10, or the fragment set forth in SEQ ID NO:11, or the fragment set forth in SEQ ID NO:12, or the fragment set forth in SEQ ID NO:13, or the fragment set forth in SEQ ID NO:14, or the fragment set forth in SEQ ID NO:15, or the fragment set forth in SEQ ID NO:16, or the fragment set forth in SEQ ID NO:17, or the fragment set forth in SEQ ID NO:18, or the fragment set forth in SEQ ID NO:19, or the fragment set forth in SEQ ID NO:20, or the fragment set forth in SEQ ID NO:21, or the fragment set forth in SEQ ID NO:22, or the fragment set forth in SEQ ID NO:23, or the fragment set forth in SEQ ID NO:24, or the fragment set forth in SEQ ID NO:25, or the fragment set forth in SEQ ID NO:26, or the fragment set forth in SEQ ID NO:27, or the fragment set forth in SEQ ID NO:28, or the fragment set forth in SEQ ID NO:29, or the fragment set forth in SEQ ID NO:30, or the fragment set forth in SEQ ID NO:31, or the fragment set forth in SEQ ID NO:32, or the fragment set forth in SEQ ID NO:33, or the fragment set forth in SEQ ID NO:34. The invention also relates to a variant of any of the above fragments or any other fragment described herein.

25

Preferably, the fragment is selected from the group of fragments set forth in SEQ ID NO:7-16, such as the fragment set forth in SEQ ID NO:7, or the fragment set forth in SEQ ID NO:8, or the fragment set forth in SEQ ID NO:9, or the fragment set forth in SEQ ID NO:10, or the fragment set forth in SEQ ID NO:11, or the fragment set forth in SEQ ID NO:12, or the fragment set forth in SEQ ID NO:13, or the fragment set forth in SEQ ID NO:14, or the fragment set forth in SEQ ID NO:15, or the fragment set forth in SEQ ID NO:16 or a variant of any of these fragments.

30

Compositions of the invention

35

Compositions of the invention comprising one or more of polypeptides of the invention can be used in various methods and for various applications as described below. Having more than one polypeptide of the invention in such a composition can

have important advantages. For instance, immunisation or vaccination may be more effective when several polypeptides or fragments are introduced at the same time.

Thus, in a main aspect the invention relates to a composition comprising one or more extracellular *Aspergillus* polypeptides or polypeptide fragments of the invention. Preferred compositions of the invention are ones that comprise one or more preferred polypeptides of the invention, i.e. the polypeptides described above. Thus, any preferred polypeptide of the invention can be used to generate a preferred composition of the invention. A preferred composition of the invention is a pharmaceutical composition comprising one or more polypeptide(s) and/or one or more polypeptide fragments of the invention and a pharmaceutically-acceptable carrier.

Cssl and GAPDH-B

Two extracellular polypeptides that were identified by the inventors are of particular interest, namely Cssl and GAPDH-B.

Cssl

This document presents data indicating the first identifications of Cssl, a novel cell-surface-exposed/secreted protein. This protein had previously been hypothesised based on the output of a gene prediction programme. However, the inventors' studies have confirmed the existence of this protein and have revealed it to be a conidial cell-wall-associated protein that is exposed on the surface while also being secreted/released into the surrounding milieu. The function of this protein is yet to be determined. However, its location within the diffusate is interesting in light of the documented abilities of diffusate to suppress the immune responses (Hobson RP (2000) Med. Mycol. 38, 133-141). Attempts to identify the protein(s) responsible for this suppressing activity have to date been unsuccessful. Without being limited to any specific theory, it is possible that Cssl is responsible for these functions, but that they have not been attributed to it due to the basic difficulties in performing molecular biology studies in *Aspergillus fumigatus*. It is interesting to note that the protein displays homology to LANA, a transcriptional regulator of Herpes virus (see below under Examples). Again without limitation to a specific theory, the possibility exists that Cssl possesses a similar function. If so, one could envisage it functioning as an extracellular sensor that transmits signals into the interior of the fungus. Alternatively, this protein may become active upon uptake into the host cell, where it

utilises its transcriptional activities to interfere with host processes, to the benefit of the fungus. Other possible functions of this protein may include roles in adhesion, invasion, conidial cell-wall processing or enzymatic digestion of host proteins.

5 **GAPDH-B**

The inventors have been the first to identify GAPDH-B, the polypeptide of SEQ ID NO:3. In one aspect, the invention relates to the sequence set forth in SEQ ID NO:3, and variants thereof. Furthermore, the invention relates to use of the polypeptide set forth in SEQ ID NO:3 in any of the methods or preferred methods of the invention.

10

GAPDHs are documented to function in glycolysis. Without being limited to a particular theory, the cell-surface localisation of GAPDH-B might suggest a role for this protein in the initiation of germination. It would seem logical to assume that dormant conidia are more prone to germination when environmental conditions become more favourable for growth and propagation of the species. One requirement for growth is a carbon source, e.g., glucose. However, the dormant conidia must have some way of detecting external environmental conditions while in its state of low metabolic activity. It is possible that the presence of glycolytic enzymes on the cell surface could result in the production of glucose by-products that may communicate to the cell that the external environment is of sufficient status to support propagation of the species. The protein may alternatively or additionally function in other processes such as adhesion, invasion, intracellular motility or intracellular survival. It is interesting to note that GAPDH proteins possess the capability to bind to cytoskeletal components (see e.g. Tisdale (2002) J. Biol. Chem. 277, 3334-3341). This feature may provide conidia with a mechanism by which it can traverse host cells in order to reach the basal membranes and cause invasive disease.

15

20

25

Production of polypeptide and fragments

30 The polypeptides and fragments of the invention can be produced synthetically by conventional techniques known in the art. Alternatively, they can be produced recombinantly in heterologous host cells. Thus, the invention also encompasses polynucleotide sequences encoding polypeptides and fragments of the invention, expression vectors comprising such polynucleotides, and host cells transformed or
35 transfected with such polynucleotides or expression vectors. Suitable host cells can

be mammalian cells, e.g. CHO, COS or HEK293 cells. Alternatively, insect cells, bacterial cells or fungal cells can be used. In preferred embodiments, yeast cells or cells from other *Aspergillus* species than *A. fumigatus* are used. Methods for heterologous expression of polynucleotide sequences in the cell types listed above and subsequent purification of the produced polypeptides are well-known to those skilled in the art.

Preferably, polypeptides, fragments and polynucleotides of the invention are isolated.

Vaccination and generation of antibodies

Exposure of a fungal polypeptide or a fragment thereof to the extracellular space often allows it to be detected by the immune system of a host organism. If such a polypeptide furthermore has a relatively high copy number, such as is the case for the extracellular polypeptides of this invention, such a polypeptide or a fragment thereof becomes particularly suitable as a target for antibodies.

In an important aspect, the invention relates to use of any one or more of the polypeptides, polynucleotides or compositions as defined herein for the manufacture of a medicament. Such a medicament can preferably be used for prevention (i.e. prophylactic treatment) of *Aspergillus* infections in a mammal. In such use the polypeptide, polynucleotide or composition is used for active immunisation or vaccination. Accordingly, the invention also relates to a medicament for treating *Aspergillus* infections comprising a polypeptide, polynucleotide or composition of the invention as an active ingredient. Furthermore, the invention relates to a method of treatment comprising the step of administering to an individual a pharmaceutically effective amount of any of the polypeptides, polynucleotides or compositions of the invention. Preferably, the treatment generates a protective immune response. Preferably, the medicament is used for the treatment or prophylactic treatment of a human being. Preferred embodiments include the use of any of the polypeptides set forth in SEQ ID NO:1,2 or 3 or fragments of these polypeptides for said manufacture of said medicament or said method of treatment, preferably any of the preferred polypeptide fragments defined herein.

In another aspect, the invention relates to a method for raising specific antibodies to a polypeptide in a non-human mammal comprising the steps of

- a. providing a polypeptide selected from the group of polypeptides set forth in SEQ ID NOs: 1-6 or a polypeptide selected from the group of the polypeptide fragments as defined in the present application,
- b. introducing a composition comprising said polypeptide into said animal,
- c. raising antibodies in said animal, and
- d. isolating and optionally purifying the antibodies.

In preferred embodiments of this method, said polypeptide is selected from the group of SEQ ID NOs: 1, 2, 3, 5, and 6. In a more preferred embodiment, the polypeptide that is provided is Cssl (SEQ ID NO: 1) or a fragment thereof, preferably a fragment comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO: 7, 8, 17, 26, 28, 29 and/or 30, or a variant of said polypeptide. In another more preferred embodiment, the polypeptide that is provided is hydrophobin (SEQ ID NO: 2) or a fragment thereof, preferably a fragment comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO: 9, 10, 18 and/or 19, or a variant of said polypeptide. In a further more preferred embodiment GAPDH-B (SEQ ID NO: 3) or a fragment thereof, preferably a fragment comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO: 11, 12, 20, 21, 22, 31, 32 and/or 33, or a variant of GAPDH-3 or the fragment is provided. In a still further more preferred embodiment, the polypeptide that is provided is catalase A (SEQ ID NO: 6) or a fragment thereof, preferably a fragment comprising one or more residues of the amino-acid sequence set forth in SEQ ID NO: 34, or a variant of said polypeptide.

In other preferred embodiments, a fragment selected from the group of SEQ NO: 7-34 is provided, preferably a fragment selected from the group of SEQ ID NO: 7-16, such as the fragment set forth in SEQ ID NO: 7, or the fragment set forth in SEQ ID NO: 8, or the fragment set forth in SEQ ID NO: 9, or the fragment set forth in SEQ ID NO: 10, or the fragment set forth in SEQ ID NO: 11, or the fragment set forth in SEQ ID NO: 12, or the fragment set forth in SEQ ID NO: 13, or the fragment set forth in SEQ ID NO: 14, or the fragment set forth in SEQ ID NO: 15, or the fragment set forth in SEQ ID NO: 16.

Raising of antibodies or immunisation may be done in different ways, such as raising anti-protein antibodies indirectly using DNA immunisation techniques or directly using the polypeptide or a fragment thereof. The polypeptide may be administered to said mammal more than once, such as twice, for example 3 times, such as 3 to 5
5 times, for example 5 to 10 times, such as 10 to 20 times, for example 20 to 50 times, such as more than 50 times. It is also possible that different polypeptides or fragments are administered to the same mammal, either simultaneously or sequentially in any order. Administration may be done by any suitable method, for example parenterally, orally or topically. Preferably, however it is administered by injection, for
10 example intramuscular, intradermal, intravenous or subcutaneous injection, more preferably by subcutaneous or intravenous injection.

Methods for determining suitable protocols for immunisation and raising antibody responses, such as determining dosage, use of adjuvants and/or pharmaceutically
15 acceptable carriers are known to those skilled in the art. For the production of antibodies to a polypeptide, various host animals can be immunised by injection with the polypeptide or a fragment thereof. Such host animals can include but are not limited to rabbits, mice, and rats. Various adjuvants can be used to increase the immunological response, depending on the host species, including, but not limited to,
20 Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*.

25 In another main aspect, the invention relates to antibodies capable of specifically recognising and binding one of the extracellular polypeptides selected from the group of SEQ ID NOs:1-6 and fragments as defined herein. Preferred are antibodies that specifically recognise and bind the polypeptide of SEQ ID NO:1, or the
30 polypeptide of SEQ ID NO:2, or the polypeptide of SEQ ID NO:3, or the polypeptide of SEQ ID NO:6. The invention also relates to pharmaceutical compositions comprising such antibodies and a pharmaceutically-acceptable carrier.

35 Antibodies can be used for passive immunisation of mammals, preferably human beings, more preferably immunocompromised patients. A treatment with antibodies

can be done to cure or to prevent *Aspergillus* infections. Thus, the invention relates to use of an antibody as defined herein for the manufacture of a medicament, preferably a medicament for the treatment of fungal infections or the prophylactic treatment (prevention) of fungal infections, preferably *Aspergillus* infections.

5 Accordingly, the invention also relates to a method of treatment comprising the step of administering to an individual a pharmaceutically-effective amount of an antibody of the invention as defined herein, and to a medicament for treating *Aspergillus* infections comprising an antibody of the invention as an active ingredient.

10 Antibodies of the invention may be mechanistically divided into the following preferred groups:

1. Function-inhibiting antibodies that work as an antifungal (affect the viability of the fungus). Such antibodies should be effective regardless of the immune status of the patient.

15 2. Opsonising antibodies that are designed to enhance phagocytic killing. Effectiveness of such antibodies may depend on the immune status of the patient, but it is very well possible that they will enhance phagocytic killing even in compromised patients.

20 3. Antibodies conjugated to a therapeutic moiety such as a toxin or fungicidal agent, e.g. ricin or radioisotopes, directed against fungal surface components. Techniques for conjugating a therapeutic moiety to antibodies are well known, see, e.g. Thorpe et al.(1982) Immunol. Rev. 62, 119-158. These antibodies should also be effective regardless of the immune status of the patient.

25 An antibody with or without a therapeutic moiety conjugated to it can be used as a therapeutic that is administered alone or in combination with chemotherapeutics or other therapeutic agents.

30 Preferably, antibodies of the invention are capable of reducing *Aspergillus* growth *in vitro* to less than 50%, such as less than 25%, for example less than 10%, such as less than 5% of a control without antibody added.

35 Antibodies include polyclonal antibodies, monoclonal antibodies, human, humanised or chimeric antibodies, single-chain antibodies, and also Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic

antibodies, hybrids comprising antibody fragments, and epitope-binding fragments of any of the these. The term also includes mixtures of monoclonal antibodies.

5 Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunised with an antigen, such as one of the extracellular polypeptides identified by the inventors, or a fragment, epitope or variant thereof. For the production of polyclonal antibodies, host animals can be immunised by injection with the polypeptide supplemented with adjuvants. The antibody titer in the immunised animal can be monitored over time by standard techniques, such as
10 ELISA using immobilised polypeptide. If desired, the antibody molecules can be isolated from the animal, for instance from the blood, and further purified by well-known techniques, such as protein-A chromatography, to obtain the IgG fraction. Thus, in a preferred embodiment, the above described method for generating an immune response comprises a step d. of isolating and purifying antibodies
15 generated in said immune response.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular epitope, can be obtained by any technique which provides for the production of antibody molecules by continuous cell-lines in culture. These include,
20 but are not limited to the hybridoma technique of Kohler and Milstein ((1975) Nature 256, 495-497; and U.S. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4, 72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80, 2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies can
25 be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the monoclonal antibody of this invention can be cultivated *in vitro* or *in vivo*.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal
30 antibody directed against a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage-display library) with the polypeptide of interest or a fragment thereof. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612).
35

Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. 5,223,409; WO 92/18619; WO 91/17271; WO 92/20791 ; WO 92/15679 ; WO 93/01288; WO 92/01047; WO 92/09690; WO 90/02809; Fuchs et al. (1991) Bio/Technology 9: 1370-1372; Hay et al.(1992) Hum. Antibod. Hybridomas 3, 81-85; Huse et al. (1989) Science 246, 1275-1281; and Griffiths et al. (1993) EMBO J. 12, 725-734.

Additionally, recombinant antibodies, such as chimeric and humanised monoclonal antibodies comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. (See, e.g., U.S. 4,816,567; and U.S. 4,816,397, which are incorporated herein by reference in their entirety.) Humanised antibodies are antibody molecules from non-human species having one or more complementarily determining regions from the non-human species and a framework region from a human immunoglobulin molecule. (See, e.g. U.S. 5,585,089, which is incorporated herein by reference in its entirety.) Such chimeric and humanised monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in WO 87/02671 ; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; WO 86/01533; U.S. 4,816,567; European Patent Application 125,023. Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et al. (1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al. (1987) Cancer Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-1559; Morrison (1985) Science 229:1202-1207; Oi et al. (1986) Bio/Techniques 4:214; U.S. Pat. No. 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeven et al. (1988) Science 239:1534-1536; Beidler et al. (1988) J. Immunol. 141:4053-4060; and Westin Kwon et al. (2002) Clin. Diagn. Lab. Immunol. 9, 201-204.

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced using transgenic mice which are

incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. The transgenic mice are immunised in the normal fashion with a selected antigen, e.g., all or a fragment of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can
5 e.g. be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harboured by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies. For an overview of this technology for producing human
10 antibodies, see Lonberg and Huszar (1995) *Int. Rev. Immunol.* 13: 65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g. U.S. 5,625,126; U.S. 5,633,425; U.S. 5,569,825; U.S. 5,661,016; and U.S. 5,545,806. Completely human antibodies which recognise a selected epitope can be generated
15 using a technique referred to as "guided selection". In this approach a selected non-human monoclonal antibody, e.g. a mouse antibody, is used to guide the selection of a completely human antibody recognising the same epitope (see Jespers et al. (1994) *Bio/Technology* 12, 899-903).

20 Suitable methods for producing human monoclonal antibodies have furthermore been described in WO 03/017935, WO 02/100348 and US 2003 091561.

Antibody fragments which recognise specific epitopes can be generated by known techniques. For example, such fragments include but are not limited to: F(ab')₂
25 fragments which can be produced by pepsin digestion of the antibody molecule and Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries can be constructed (Huse et al. (1989) *Science* 246, 1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

30 Antibodies of the invention also include bispecific antibodies having two binding specificities, of which at least one is a specificity for a polypeptide selected from the group of SEQ ID NO:1-6, preferably selected from the group of SEQ ID NOs:1-4.

Antibodies of the present invention may also be described or specified in terms of their binding affinity to a target polypeptide product. Preferred binding affinities include those with a dissociation constant or K_d less than $5 \times 10^{-6}M$, such as less than $10^{-6}M$, e.g. less than $5 \times 10^{-7}M$, such as less than $10^{-7}M$, e.g. less than $5 \times 10^{-8}M$, such as less than $10^{-8}M$, e.g. less than $5 \times 10^{-9}M$, such as less than $10^{-9}M$, e.g. less than $5 \times 10^{-10}M$, such as less than $10^{-10}M$, e.g. less than $5 \times 10^{-11}M$, such as less than $10^{-11}M$, e.g. less than $5 \times 10^{-12}M$, such as less than $10^{-12}M$, e.g. less than $5 \times 10^{-13}M$, such as less than $10^{-13}M$, e.g. less than $5 \times 10^{-14}M$, such as less than $10^{-14}M$, e.g. less than $5 \times 10^{-15}M$, or less than $10^{-15}M$.

Binding partners and inhibitors of extracellular polypeptides

In addition to antibodies, it is of interest to identify other types of binding partners to extracellular polypeptides. Extracellular polypeptides of a pathogenic fungus often interact with the host organism. Any type of binding partner of an extracellular polypeptide may interfere with host-pathogen interaction. Binding partners may thus antagonise the pathogenicity of the fungus.

Identification of binding partners of the extracellular polypeptides set forth in SEQ ID NO:1-6, or fragments thereof, is another main aspect of this invention. This may be done using biochemical or cell-based methods.

Biochemical methods

In a main aspect, the invention relates to a method for identifying a binding partner of a polypeptide of the invention and/or a polypeptide selected from the group of SEQ ID NOs:1-6, comprising the steps of

- a. providing a polypeptide of the invention as defined herein or a polypeptide selected from the group of SEQ ID NOs:1-6,
- b. contacting said polypeptide with a putative binding partner, and
- c. determining whether said putative binding partner is capable of binding to said polypeptide.

In a preferred embodiment of this method of the invention, said polypeptide is selected from the group of SEQ ID NOs:1,2,3,5 and 6, such as the polypeptide set forth in SEQ ID NO:1, e.g. the polypeptide set forth in SEQ ID NO:2, such as polypeptide set forth in SEQ ID NO:3, e.g. the polypeptide set forth in SEQ ID NO:5,

such as the polypeptide set forth in SEQ ID NO:6. In other preferred embodiments, an exposed domain, an epitope or a fragment of one of the polypeptides set forth in SEQ ID NOs:1-6 comprising one or more amino-acid residues of the sequences set forth in SEQ ID NO: 7-34 is provided in step a. In further preferred embodiments, a
5 fragment selected from the group of SEQ NO:7-34 is provided, preferably a fragment selected from the group of SEQ ID NO:7-27, or a variant or fragment of any of the amino-acid sequences set forth in SEQ ID NO:7-27.

10 In preferred embodiments of this method, the polypeptide or fragment thereof is provided immobilised on a solid support, such as e.g. a column or microtiter plate, and, after the contacting step, it is determined whether or not the putative binding partner has bound to the solid support. Immobilisation of the polypeptide or fragment thereof may be through direct binding to the solid support, or through indirect binding e.g. using a specific antibody. In preferred embodiments, a washing step is
15 performed between the contacting step and the determination step, in order to improve the specificity of detection. In further preferred embodiments, the putative binding partner is labelled. The putative partner may be labelled before the contacting takes place. Alternatively, labelling may also be performed after the contacting step. Furthermore, in some embodiments of this method, immobilisation
20 may be performed after the polypeptide or fragment thereof has been bound to the binding partner. In preferred embodiments, the method is repeated for a plurality of putative binding partners. Putative binding partners include host-derived molecules.

25 Alternatively, a binding partner of a polypeptide of the invention or of a polypeptide selected from the group of SEQ ID NO:1,2,4,5 and 6 may be identified as follows: purified host membranes are electrophoretically separated, blotted over to a membrane and incubated with the polypeptide of interest or fragment thereof. Binding can then be detected using antibodies specific for the polypeptide of interest or fragment thereof. The host binding partner to which the polypeptide or fragment
30 thereof has bound can subsequently be identified by elution from the blot and subsequent analysis by mass spectrometry, or by any other technique known in the art.

35 If the binding partner of an extracellular polypeptide of a pathogenic organism is a host-derived molecule, then such an interaction between the extracellular

polypeptide and the host may be important for the virulence of the fungus. Compounds that interfere with the interaction of the extracellular polypeptide and the host binding partner may thus be suitable for prevention or treatment of fungal infections. Accordingly, another method of the invention relates to a method of

5 identifying an inhibitor of the interaction of an extracellular *Aspergillus* polypeptide or fragment thereof with a host-derived binding partner comprising the steps of:

- a. providing a polypeptide selected from the group of SEQ ID NO:1-6, or a fragment thereof,
- b. providing a host-derived binding partner of said polypeptide
- 10 c. contacting said polypeptide with said host-derived binding partner in the absence of a putative inhibitor of said interaction
- d. contacting said polypeptide with said host-derived binding partner in the presence of said putative inhibitor
- e. determining whether the strength of the binding of said polypeptide to said host-
- 15 derived binding partner resulting from step d. is reduced as compared to that resulting from step c.

In some embodiments, step c. and d. may be performed in two different sample compartments. In other embodiments, step d. may be performed by adding the putative inhibitor to the mixture of step c. In preferred embodiments, a fragment

20 selected from the group of SEQ ID NO:7-34 is provided in step a. In other preferred embodiments, the polypeptide of SEQ ID NO:1,2,3,5 or 6 is provided. In further preferred embodiments, the method is repeated for a plurality of putative inhibitors. Of further particular interest are binding partners that inhibit an activity of an extracellular polypeptide. Such activity may be enzymatic activity, transport activity,

25 or any type of other biochemical or cellular activity, preferably enzymatic activity. Inhibitors of GAPDH, enolase or catalase may be screened for using known biochemical assays of the enzymes, such as the catalase assay kit of CALBIOCHEM, cat. no. 219263, and the assays described in Bartolini et al. (2003) J. Chromatogr. 987, 331-340; Lal et al. (1991) Plant Mol. Biol. 16, 787-795; Machida et al. (1996) Biosci Biotechnol Biochem 60, 161-163; and Maitra and Lobo (1971) J Biol Chem 246, 475-88.

30

Cell-based methods

Reducing the level of an extracellular polypeptide, by deletion or disruption of the

35 structural gene for it or by down-regulating gene expression (see below), may affect

5 a fungal cell. The cell may become more sensitive to cytotoxic compounds. Especially for extracellular polypeptides, a reduction of their level may affect the function of the cell's exterior parts, such as the plasma membrane or cell wall, in preventing compounds of entering the cell. Thus, reduction of the level of an extracellular polypeptide can make a cell more 'permeable' for various compounds.

An aspect of the present invention relates to a method for identifying a compound with anti-*Aspergillus fumigatus* activity comprising the steps of

10 a. providing a sensitised cell which has a reduced level of a polypeptide selected from the group of SEQ ID NO:1-6, and

b. determining the sensitivity of said cell to a putative inhibitor, for instance by a growth assay.

In a preferred embodiment, a sensitised cell which has a reduced level of a polypeptide selected from the group of SEQ ID NO:1,2,3,5 and 6 is provided in step

15 a. In an even more preferred embodiment of the method, a sensitised cell which has a reduced level of Cssl (SEQ ID NO:1), hydrophobin (SEQ ID NO:2), GAPDH (SEQ ID NO:3), or catalase A (SEQ ID NO:6) is provided.

The rationale behind this approach is that a cell with a lower level of the extracellular polypeptide will exhibit increased sensitivity to cytotoxic compounds, allowing

20 identification of antifungal compounds with low potency that are missed when using wild-type cells for the assay. Compounds identified by this method will be often need to be modified in order to improve potency. This can be done by chemical modification. In preferred embodiments, the method is repeated for a plurality of

25 putative binding partners.

Inhibition of the activity of an extracellular polypeptide may affect the viability (i.e. survival, growth and/or proliferation) of the fungus. Of particular interest is inhibition of extracellular polypeptides that are essential for viability of *A. fumigatus*.

30 Essentiality of an *Aspergillus* gene may be investigated e.g. using regulatable expression as described in WO 02/086090. Inhibitors of essential extracellular polypeptides may not need to enter the fungal cell to be able to affect its viability. Thus, generally fewer requirements are posed on the structure of an inhibitor of essential extracellular target polypeptide than on an inhibitor of an intracellular

35 target, to be effective as an antifungal agent.

Thus, the invention relates to a method for finding an inhibitor of an extracellular *Aspergillus fumigatus* polypeptide comprising the steps of

- a. providing two cells which differ in the level of a polypeptide selected from the group of SEQ ID NO:1-6,
- b. determining the sensitivity of said cells to a putative inhibitor, for instance by a growth assay, and
- c. determining whether said two cells are differently affected by the presence of said putative inhibitor.

The rationale behind this approach is that the viability of a cell with a lower activity of the essential polypeptide will be more affected by an inhibitor of the polypeptide than the viability of the cell with a higher level. If the two cells are differently affected, this is an indication that the inhibitor acts on the target or in the same biochemical pathway. In a preferred embodiment of the method, said polypeptide is Cssl (SEQ ID NO:1), GAPDH (SEQ ID NO:3), or catalase A (SEQ ID NO:6).

In some embodiments of the method, the two cells with different activity of the polypeptide of interest are a wild-type cell (or other cell with wild-type activity of the gene of interest) and a sensitised cell with a reduced activity of the polypeptide of interest. In some embodiments, the different or reduced level in the sensitised cell can be a different or reduced expression level of the gene of interest (resulting in a different or reduced copy number of the polypeptide). This can be accomplished by putting the gene under control of a regulatable promoter or by regulatable expression of an antisense RNA which inhibits translation of an mRNA encoding the essential polypeptide. In other embodiments, the different or reduced activity can be a different or reduced activity of the polypeptide of interest, e.g. due to a mutation, such as a temperature-sensitive mutation. In preferred embodiments, the method is repeated for a plurality of putative binding partners.

Suitable ways of generating sensitised cells and of using these in screening for inhibitors have been described in WO 02/086090. Sensitised cells may be obtained by growing a conditional-expression *A. fumigatus* mutant strain in the presence of a concentration of inducer or repressor which provides a level of a gene product required for fungal viability such that the presence or absence of its function becomes a rate-determining step for viability. A number of suitable regulatable promoters for constructing such conditional-expression mutants of *Aspergillus* is

described in WO 02/086090, page 76, line 34 through page 85, line 4. For example, if the regulatable promoter is repressed by tetracycline, the conditional-expression *Aspergillus fumigatus* mutant strain may be grown in the presence of partially repressing concentrations of tetracycline. The sub-lethal concentration of inducer or repressor may be any concentration consistent with the intended use of the assay. For example, the sub-lethal concentration of the inducer or repressor may be such that growth inhibition is at least about 10%, such as at least about 25%, e.g. at least about 50%, such as at least about 75%, e.g. at least 90%, such as at least 95%.

Similarly, the virulence or pathogenicity of cells exposed to a candidate compound which express a rate-limiting amount of a gene product required for virulence or pathogenicity may be compared to the virulence or pathogenicity of cells exposed to the candidate compound in which the level of expression of the gene product required for virulence or pathogenicity is not rate-limiting. In such methods, test animals are challenged with the conditional-expression *A. fumigatus* mutant strain and fed a diet containing the desired amount of tetracycline and the candidate compound. Thus, the conditional-expression mutant strain infecting the test animals expresses a rate limiting amount of a gene product required for virulence or pathogenicity (i. e. the conditional-expression mutant cells in the test animals are sensitised). Control animals are challenged with the conditional-expression mutant strain and are fed a diet containing the candidate compound but lacking tetracycline. The virulence or pathogenicity of the conditional-expression *A. fumigatus* mutant strain in the test animals is compared to that in the control animals. For example, if a significant difference in growth is observed between the sensitised conditional-expression mutant cells (i. e. the cells in animals whose diet included tetracycline) and the non-sensitised cells (i. e. the conditional-expression mutant cells animals whose diet did not include tetracycline), the candidate compound may be used to inhibit the virulence or pathogenicity of the organism or may be further optimised to identify compounds which have an even greater ability to inhibit the virulence or pathogenicity of the organism. Virulence or pathogenicity may be measured using the techniques known in the art.

In another embodiment of the cell-based assays of the present invention, sensitised cells are obtained by reduction of the level activity of a polypeptide required for fungal viability using a mutation, such as a temperature-sensitive mutation, in the

polypeptide. Growing such cells at an intermediate temperature between the permissive and restrictive temperatures produces cells with reduced activity of the gene product. It will be appreciated that the above method may be performed with any mutation which reduces but does not eliminate the activity or level of the gene product which is required for fungal viability. This approach may also be combined with the conditional-expression approach. In this combined approach, cells are created in which there is a temperature-sensitive mutation in the gene of interest and in which this gene is also conditionally-expressed.

When screening for inhibitors of an essential polypeptide, growth inhibition can be measured by directly comparing the amount of growth, measured by the optical density of the culture relative to uninoculated growth medium, in an experimental sample with that of a control sample. Alternative methods for assaying cell proliferation include measuring green fluorescent protein (GFP) reporter construct emissions, various enzymatic activity assays, and other methods well known in the art. Other parameters used to measure viability include e.g. colony forming units. The above method may be performed in solid phase, liquid phase, a combination of the two preceding media, or *in vivo*. Multiple compounds may be transferred to agar plates and simultaneously tested using automated and semi-automated equipment.

Cell-based assays of the present invention are capable of detecting compounds exhibiting low or moderate potency against the target molecule of interest because such compounds are substantially more potent on sensitised cells than on non-sensitised cells. The effect may be such that a test compound may be two to several times more potent, e.g. at least 10 times more potent, such as at least 20 times more potent, e.g. at least 50 times more potent, such as at least 100 times more potent, e.g. at least 1000 times more potent, or even more than 1000 times more potent when tested on the sensitised cells as compared to non-sensitised cells.

A mutant *A. fumigatus* strain that overexpresses an extracellular polypeptide can also be used to identify a compound that inhibits such a polypeptide. If the compound is cytotoxic, overexpression of the target polypeptide can make cells more resistant. Thus, the invention also relates to a method for finding an inhibitor of an extracellular *Aspergillus* polypeptide comprising the steps of

- a. providing two cells which differ in the activity of a polypeptide selected from the group of (SEQ ID NO:1-6), wherein one cell contains a substantially wild-type copy number of said polypeptide and the other cell contains higher than wild-type activity of said polypeptide
 - 5 b. determining the sensitivity of said cells to a putative inhibitor, for instance by a growth assay, and
 - c. determining whether or not said two cells are differently affected by the presence of said putative inhibitor.
- 10 Preferably, the two cells differ in the activity of a polypeptide selected from the group of SEQ ID NO:1,2,3,5 and 6, such as the polypeptide of SEQ ID NO:1, e.g. the polypeptide of SEQ ID NO:2, such as the polypeptide of SEQ ID NO:3, e.g. the polypeptide of SEQ ID NO:5, such as the polypeptide of SEQ ID NO:6.
- 15 As also overexpression of polypeptides that are not the cellular target of an inhibitor can make cells resistance to an inhibitor, inhibition of the target polypeptide of interest by said inhibitor will need to be verified by other means, such as e.g. a biochemical assay.
- 20 Overexpression may be achieved using strong promoters, e.g. the *A. niger* Pgla A promoter, the *A. nidulans* promoter alcA(p), or the constitutive promoters PGK- (phosphoglycero-kinase), GPD-(glucose-6-phosphate dehydrogenase) or ENO (enolase) promoters or regulated promoters such as ADH2, PHO5, GAL1, GAL10, CUP1 or HSP70. Other useful promoters include the ones described in Adams et al.
- 25 (1998) Microbiol. Mol. Biol. Rev. 62, 35-54; Adams et al. (1988) Cell 54, 353-362; Andrianopoulos and Timberlake (1991) Plant Cell 3, 747-748; Gwynne et al. (1987) Gene 51:205-216; Lockington et al. (1985) Gene 33:137-149.
- 30 In addition to inhibitors of a biochemical or other cellular activity of an extracellular polypeptide, the cellular methods described above may identify compounds that reduce the expression level of a target, and thereby its copy number, e.g. by interfering with gene regulation.

In preferred embodiments of the any of the cell-based- or biochemical methods for finding binding partners or inhibitors, the method is repeated for a plurality of candidate compounds.

5 In a further aspect, the invention relates to the mutant *A. fumigatus* strains used in the cell-based methods described herein, such as strains in which the gene encoding the extracellular polypeptide is placed under the control of a heterologous regulatable promoter, strains carrying temperature-sensitive alleles of the extracellular polypeptides, and strains overexpressing the extracellular polypeptides.

10 Other methods of interfering with fungal growth by targeting essential extracellular polypeptides include suppression of gene expression using specific antisense molecules, such antisense RNA or DNA, and using ribozyme molecules specific for mRNA encoding the essential extracellular polypeptides.

15 Diagnosis

In a further main aspect, the invention relates to a method of diagnosing *Aspergillus* infection comprising the steps of

- a. providing a sample from an individual,
- 20 b. contacting said sample with an indicator moiety specific for a polypeptide as defined in any of claims 2-15, or specific for a polypeptide selected from the group of Cssl (SEQ ID NO:1), hydrophobin (SEQ ID NO:2), GAPDH (SEQ ID NO:3), and catalase A (SEQ ID NO:6), and
- c. determining whether a signal has been generated by the indicator moiety.

25 In a preferred embodiment of this method, the polypeptide of the invention is a polypeptide selected from the group of SEQ ID NO:1,2,3,5 and 6, such as the polypeptide of SEQ ID NO:1, e.g. the polypeptide of SEQ ID NO:2, such as the polypeptide of SEQ ID NO:3, e.g. the polypeptide of SEQ ID NO:5, such as the
30 polypeptide of SEQ ID NO:6. In other preferred embodiments of this method, the indicator moiety is specific for a fragment selected from the group of fragments set forth in SEQ ID NO:7-34.

In preferred embodiments, said indicator moiety is or comprises an antibody.
35 Antibodies directed against a target extracellular polypeptide or fragment thereof

can be used to detect the polypeptide in order to evaluate the abundance and pattern of expression of the polypeptide under various environmental conditions, in different morphological forms (mycelium, yeast, spores) and stages of an organism's life cycle.

5

Preferably, however, antibodies directed against a target polypeptide or fragment thereof can be used diagnostically to monitor levels of a target gene product in the tissue of an infected host as part of a clinical testing procedure, e. g., to, for example, diagnose a patient for *Aspergillus* infection or determine the efficacy of a given treatment regimen. In particular Cssl is of considerable interest for diagnostic purposes. It appears that the protein is unique to *A. fumigatus* as no significant homologues to the protein have yet been detected through the use of immunological or sequence-based procedures. Furthermore, the cell-surface and secreted nature of the protein is also favourable feature from the point of view of detecting the protein in human fluids.

10

15

Detection using antibodies can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase ; examples of suitable prosthetic group complexes include Streptavidin/biotin and avidin/biotin ; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin ; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

20

25

30

35

Various diagnostic assays employing the above indicator moieties can be set up to test samples for *Aspergillus*. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: countercurrent immuno-electrophoresis (CIEP), radioimmunoassays, radioimmunoprecipitations, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, inhibition or competi-

tion assays, and sandwich assays, immunostick (dipstick) assays, simultaneous immunoassays, immunochromatographic assays, immunofiltration assays, latex bead agglutination assays, immunofluorescent assays, biosensor assays, and low-light detection assays (see U.S. Pat. Nos. 4,376,110 and 4,486,530; see also Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988.

Detailed description of the drawings

Table 1 shows the sequences of the peptides that were identified in the AfC fractions. Shown are, for each of the five polypeptides (Cssl, Hydrophobin, GAPDH, enolase and catalase (A+B)) , the peptides that were identified in the three different fractions (diffusate, cell-surface-exposed, and cell wall), and the sequences of the peptides that were used for antibody production.

Figure 1 shows the predicted full-length polypeptide sequences of Cssl (A) (SEQ ID NO:1), hydrophobin (B) (SEQ ID NO:2), GAPDH-B (C) (SEQ ID NO:3), enolase (D) (SEQ ID NO:4), catalase B (E) (SEQ ID NO:5), and catalase A (F) (SEQ ID NO:6).

Table 2 shows some biochemical characteristics for the full-length Cssl polypeptide and for its N-terminal and its C-terminal half. 'MW' indicates molecular weight. 'Residues' indicates the number of residues.

Figure 2 shows the predicted antigenicity indices of Cssl (A) and hydrophobin (B) residues, predicted according to Jameson and Wolf (1988).

Figure 3: Alignment of the predicted protein sequences for GAPDH-A (AfA), GAPDH-B (AfB), and GAPDH-C (AfC) from *Aspergillus fumigatus*. Residues that are identical in all three proteins are presented on a dark background. Peptides of GAPDH-B that have been identified by MS have been underlined.

Examples

Example 1. Identification of peptides in extracts of *A. fumigatus*.

5 A number of protein purification procedures were used to facilitate identification of *A. fumigatus* proteins that are secreted, cell surface exposed or cell-wall associated. Proteins were then identified from these extracts via mass spectrometry techniques.

10 *Culture of A. fumigatus.* *A. fumigatus* conidia (AfC) of strain NCPF 2140 or ATCC 46640 were routinely prepared by inoculation of malt agar plates with AfC and subsequent growth at 30°C for 10 days.

15 *Preparation of a diffusible extract from A. fumigatus conidia.* *A. fumigatus* Diffusate (AfD) was routinely prepared as follows. AfC (2×10^8) were added to water (0.5 ml) containing protease inhibitors (Roche, cat. no. 1 697 498) and the mixture was vortexed and then sonicated to solubilise the AfC. The resultant solution was incubated for 1 hour at 37°C, with shaking. AfD was then separated from washed spores by passage through a 0.2 µm filter, or, by centrifugation (3000 x g) of washed spores and passage of the AfD through a 0.2 µm filter.

20 *Preparation of surface-exposed protein extracts from A. fumigatus conidia.* Washed AfC (2.0×10^{10}) were resuspended in 1 ml of PBS (0.01 M phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium chloride, pH 7.4) containing a reducing agent (10 mM Tris 2-carboxy-ethyl phosphine (TCEP)) and incubated for 20 min at room temperature. AfC were pelleted by centrifugation (20000 x g, 30 min) and washed in 25 PBS to remove TCEP before being resuspended in a trypsin-solution (seq. grade modified porcine trypsin, Promega cat. no. V5111, 20 µg/ml PBS) and incubated for 30 min at room temperature. AfC were then removed by centrifugation and filtration. To get rid of any conidia in the supernatant, the supernatant was purified using a 30 YM-10 column (from Millipore, cat. no. 4206, 5000xg, 4°C for 30 min.) and the supernatant was incubated over night at 37°C with shaking at 40 rpm. The supernatant was concentrated using a SpeedVac concentrator, 1 µl was added to 6 µl 5% formic acid, and the resultant solution was analysed via mass spectrometry.

35 *Preparation of cell wall extracts from A. fumigatus conidia.* AfC solutions (20 ml; 1.8×10^8 conidia/ml) were prepared in both PYG (C rich) (Peptone-yeast extract and

glucose: 0.1% peptone, 0.1% g yeast extract and 0.3% glucose) and HBSS (C poor) (HANKS 1X from Gibco, Invitrogen (cat. no. 24020-083)) media. These solutions were vortexed for 3 min, sonicated for 5 min and then incubated for 4 hours at 37°C with shaking (160 rpm). AfC were pelleted by centrifugation (6000 x g, 30 min) and the supernatant from the HBSS incubation was collected and passed through a 0.2 µm filter. The supernatant from the PYG was discarded. Both AfC pellets were washed with 5 ml HBSS and pelleted as before. To each pellet 1 ml of lysis buffer (2% Triton, 1% SDS, 10 mM Tris (pH=2), 1 mM EDTA, 100 mM NaCl, 1 proteinase inhibitor tablet (Roche, cat. no. 1 697 498) and approx. 500 µl glass beads (200-300 microns) were added. The resultant solution was then incubated in a water bath sonicator for 40 min, vortexed for 30 min, chilled on ice for 5 min, and finally vortexed for another 30 min. Glass beads were then removed from the sample and conidial walls were sedimented by centrifugation at 1200 x g for 10 min. The supernatant was removed and stored for future use.

Conidial wall enriched pellets were washed three times with 1 ml of cold distilled water, resuspended in 250 µl of 2% (w/v) SDS, 1% (w/v) 2-mercaptoethanol solution and boiled for 5 min. The resultant solution was centrifuged (10,000 x g for 15 min), the supernatant was transferred to a new tube, and added to 1 ml ice-cold acetone prior to an overnight incubation at -30°C. Precipitated proteins were pelleted (20,810 x g for 45 min) and dried in a SpeedVac for 15 min to remove residual acetone. Pellets were resuspended in ddH₂O, and proteins were separated on an SDS-PAGE according to standard procedures. Resultant gels were then visualised via silver staining.

Analysis of A. fumigatus protein extracts by mass spectrometry. Analysis of *A. fumigatus* proteins separated by SDS-PAGE was performed as follows. Fragments of SDS-PAGE gels, corresponding to specific protein bands, were extracted and placed in sodium bicarbonate solution (50 mM NH₄HCO₃). These gel plugs were then washed twice with 50 mM NH₄HCO₃ in 50% ethanol for 30 min and dehydrated by incubation in 96% ethanol for 10 min. Reduction and alkylation was performed by incubating in reducing solution (50 mM DTT, 50 mM NH₄HCO₃) for 45 min at 56°C followed by a 30 min room temperature incubation in alkylation solution (55 mM iodoacetamide, 50 mM NH₄HCO₃) in the dark. Two cycles of washing and dehydration were then performed prior to the addition of 10 µl trypsin solution (12.5

ng/ μ l trypsin in 50 mM NH_4HCO_3 (seq. grade modified porcine trypsin, Promega batch no. V511X 14755007)). After 15 min an additional 20 μ l of sodium bicarbonate solution was added and the digests were incubated overnight at 37°C. Samples were then extracted twice by 30 min incubations, with shaking, in 3 μ l of 20% trifluoroacetic acid, and 20 μ l of a solution containing acetonitrile (10%) and trifluoroacetic acid (1%). Both extracts were pooled, dried down, and resuspended in 9% of 5% formic acid prior to analysis via LC-MS.

Peptide and fragment mass tolerance was set to 200 ppm and 0.5 Da, respectively. Search parameters were adjusted to include oxidation of Met, the addition of alkyl of polyacrylamide groups to Cys, and trypsin was allowed to miss one cleavage site per peptide.

Search parameters for analysis of cell surface peptide fragments were adjusted to include oxidation of Met, trypsin was allowed to miss one cleavage site on each peptide; and, peptide and fragment mass tolerance was set to 100 ppm and 0.3 Da, respectively.

Following the identification of a peptide sequence, a TBLASTN was performed against *A. fumigatus* shotgun sequences in the public domain. This identified all shotgun sequences capable of encoding the peptide fragment. These shotgun sequences were then used to extract all other shotgun sequences that shared regions of homology of at least 40 bp in length with no less than 90% identity. All appropriate shotgun sequences were then formed into a contiguous sequence using Seqman. Resulting contigs were submitted to a GenScan search using maize, arabidopsis, and human parameters. Output predicted protein sequences were then compared with the encoding nucleotide sequence and with the sequences of protein homologues to facilitate the prediction of a potentially more accurate protein sequence. Resulting predicted nucleotide and peptide sequences were then entered into appropriate in-house databases and MASCOT searches were then rerun against a database containing these newly predicted proteins.

The peptides identified in the Diffusate, Cell-surface exposed, and Cell-wall fractions are shown in Table 1. The corresponding predicted protein sequences are given in Figure 1.

Peptides from both hydrophobin and the hypothetical protein were identified in all three fractions indicating both to be cell-wall-associated proteins that are exposed on the surface of the AfC while also being secreted/released into the surrounding milieu. Based on these data we propose to name the newly identified, former hypothetical, protein Conidial Surface and Secreted protein I, Cssl. It was also interesting to note the presence of GAPDH in the AfD and cell wall; enolase in the AfD; and of cell wall located, and surface exposed variants of catalase. Since the procedures used to purify and identify these peptides are biased for proteins of high abundance, one can also conclude that they are expressed in relatively high copy numbers.

Example 2. Bioinformatic analyses

SignalP predictions were performed using the parameters recommended for a eukaryotic protein, while Antigenicity index studies were performed using the default parameters determined by DNASTar. BLAST searches were performed using default parameters.

Analysis of Cssl for the presence of a signal peptide. The group who reported the original hypothetical sequence predicted an N-terminal signal peptide of 24 residues (NCBI entry CAD29600. Protein AfA35G10.07). However, a repeat of these studies using the SignalP program with default parameters (Nielsen et al. (1997) Protein Engineering 10, 1-6) indicates the presence of a 47-residue signal peptide with predicted signal cleavage occurring between A47 and R48.

Analysis of the predicted protein sequence of Cssl.

A brief overview of the sequence of this protein reveals the two most abundant residues to be E and Q, which comprise 9.62% and 8.64%, respectively, of all residues in the protein. A closer analysis revealed that 67% of charged residues (D, E, K, R) are located in the C-terminal half of the protein (see Table 2), and 62% of hydrophobic residues (A, I, L, F, W, V) in the N-terminal half.

The sequence of Cssl was analysed via the antigenicity index programme of Jameson and Wolf (1988). This programme predicted the C-terminal half of the protein to be most antigenic (see Figure 2).

5 BLAST analysis of Cssl revealed the absence of a protein with high homology. However, a number of proteins displayed low, yet significant, levels of homology. One such protein, ORF73 of Human herpesvirus 8, is the Latency associated nuclear antigen (LAN/LANA) that is used as a marker for Kaposi's sarcoma. It displays 26% identity and 46% similarity to the C-terminal half of Cssl. This region of LANA is
10 rich in Q and E repeats and is located in the middle of the protein. It has been suggested that similar regions of acidic repeats often function in transcriptional activation in viral and cellular transcription factors (Struhl, 1995, Annu. Rev. Genet. 29, 651-674). LANA has been shown to be capable of modulating both viral and cellular gene expression (Renne et al., 2001, J. Virol. 75, 458-468).

15 *GAPDH sequences.* An attempt to construct a gene sequence for this protein revealed the presence of at least three genes in *Aspergillus fumigatus* that are capable of expressing a GAPDH-related protein. These predicted proteins have been labelled GAPDH-A, GAPDH-B, and GAPDH-C. A number of differences exist between these two proteins (see Fig 3). However, it is possible to conclude that only
20 GAPDH-B has been identified to date. An inability to identify GAPDH-A or -C, to date, could be due to a number of reasons, e.g., a failure to be expressed under laboratory conditions; or, to the absence of an appropriate predicted protein sequence in the databases. The fact that only GAPDH-B was identified in cell wall and secreted preparations indicates that this version of the protein is likely to be primarily
25 a cell-wall variant, and perhaps GAPDH-A and -C the cytoplasmic variants.

GAPDH-A and GAPDH-B share 73% identity and 85% similarity over a over a stretch of 269 residues. The more divergent GAPDH-C shares only 43% identity
30 with both GAPDH-A and GAPDH-B. An analysis of all three sequences via an InterProScan revealed all three to be GAPDH sequences. However, only proteins A and B had sequences that matched to the active-site motif ([ASV]-S-C-[NT]-T-x(2)-[LIM]). This could imply that C does not function as a true GAPDH protein. Upon closer analysis of the sequences it is apparent that C contains a V residue, instead
35 of [LIM], at the last position in the motif. Considering that V, L, M, and I are all hy-

drophobic residues, it is unlikely that the difference will result in a non-functional GAPDH active site.

5 *Homology to human proteins and essentiality to A. fumigatus.* Of the protein mentioned above, neither Cssl nor Hydrophobin have any significant human homologues. Both enolase (61% identical, 77% similar) and GAPDH (77% identical/ 83% similar), on the other hand, do have human homologues over the full length of the protein. However, due to the small size of any given epitope, and to the specificity of antibodies in general, it is likely that a suitable antibody can be found to distinguish
10 *A. fumigatus* versions from the human versions.

Peptides for antibody production

The peptides found in the mass spectrometry analysis were used for antibody production. Some of them were extended with flanking residues from the predicted or
15 known sequences.

Claims

1. A composition comprising one or more *Aspergillus* polypeptides selected from the group of

5

fragments of SEQ ID NO:1 of less than 259 amino-acid residues in length, such as less than 200, preferably less than 150, such as less than 100, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:7,8,17,26,28,29 and/or 30 and variants of said fragments;

10

fragments of SEQ ID NO:2 of less than 106 amino-acid residues in length, such as less than 75, preferably less than 50, such as less than 25 residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:9,10,18 and/or 19 and variants of said fragments;

15

polypeptides comprising SEQ ID NO:3, fragments thereof and variants thereof, with the proviso that if the polypeptide is a fragment of SEQ ID NO:3, that this fragment is not the fragment set forth in SEQ ID NO:35;

20

fragments of SEQ ID NO:4 of less than 437 amino-acid residues in length, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:13,14,23,24 and/or 25 and variants of said fragments;

25

fragments of SEQ ID NO:5 of less than 727 amino-acid residues in length, e.g. less than 400, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:15,16 and/or 27 and variants of said fragments;

30

and

5 fragments of SEQ ID NO:6 of less than 748 amino-acid residues in length, e.g. less than 400, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:34 and variants of said fragments.

2. An *Aspergillus* polypeptide selected from the group of

10 fragments of SEQ ID NO:1 of less than 259 amino-acid residues in length, such as less than 200, preferably less than 150, such as less than 100, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:7,8,17,26,28,29 and/or 30 and variants of said fragments;

15 fragments of SEQ ID NO:2 of less than 106 amino-acid residues in length, such as less than 75, preferably less than 50, such as less than 25 residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:9,10,18 and/or 19 and variants of said fragments;

20 polypeptides comprising SEQ ID NO 3, fragments thereof and variants thereof, with the proviso that if the polypeptide is a fragment of SEQ ID NO:3, that this fragment is not the fragment set forth in SEQ ID NO:35;

25 fragments of SEQ ID NO:4 of less than 437 amino-acid residues in length, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:13,14,23,24 and/or 25 and variants of said fragments;

30 fragments of SEQ ID NO:5 of less than 727 amino-acid residues in length, e.g. less than 400, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:15,16 and/or 27 and variants of said fragments;

35

and

5 fragments of SEQ ID NO:6 of less than 748 amino-acid residues in length, e.g. less than 400, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:34 and variants of said fragments.

10 3. The polypeptide of claim 2, wherein the polypeptide is a fragment comprising one or more residues of the amino-acid sequences set forth in SEQ ID NOs: 7-27, or a variant of said fragment.

15 4. The polypeptide of claim 3, wherein the polypeptide is a fragment comprising one or more residues of the amino-acid sequences set forth in SEQ ID NOs: 7-16, or a variant of said fragment.

20 5. The polypeptide of claim 3, wherein the polypeptide is a fragment comprising one or more residues of the amino-acid sequences set forth in SEQ ID NOs: 17-25 and/or SEQ ID NO:14, or a variant of said fragment.

6. The polypeptide of claim 3, wherein the polypeptide is a fragment comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO: 18, 19, 26, and/or 27, or a variant of said fragment.

25 7. The polypeptide of claim 2, wherein the polypeptide is a fragment of SEQ ID NO:1 of less than 259 amino-acid residues in length, such as less than 200, preferably less than 150, such as less than 100, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:7,8,17,26,28,29 and/or 30 or a variant of said fragment.

30

35 8. The polypeptide of claim 7, wherein the polypeptide is a fragment of SEQ ID NO:1 of less than 259 amino-acid residues in length, such as less than 200, preferably less than 150, such as less than 100, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the

amino-acid sequences set forth in SEQ ID NO:7,8,17 and/or 26, or a variant of said fragment.

- 5 9. The polypeptide of claim 2, wherein the polypeptide is a fragment of SEQ ID NO:2 of less than 106 amino-acid residues in length, such as less than 75, preferably less than 50, such as less than 25 residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:9,10,18 and/or 19, or a variant of said fragment.
- 10 10. The polypeptide of claim 2, wherein the polypeptide is a polypeptide comprising SEQ ID NO:3, or a fragment thereof or a variant of such polypeptide, with the proviso that if the polypeptide is a fragment of SEQ ID NO:3, that this fragment is not the fragment set forth in SEQ ID NO:35.
- 15 11. The polypeptide of claim 10, wherein the polypeptide a fragment of SEQ ID NO:3 of less than 171 amino-acid residues in length, such as less than 150, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:11,12,20,21,22,31,32 and/or 33
- 20 or a variant of said fragment.
- 25 12. The polypeptide of claim 10, wherein the polypeptide a fragment of SEQ ID NO:3 of less than 171 amino-acid residues in length, such as less than 150, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:11,12,20,21 and/or 22 or a variant of said fragment.
- 30 13. The polypeptide of claim 2, wherein the polypeptide is a fragment of SEQ ID NO:4 of less than 437 amino-acid residues in length, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues, in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:13,14,23,24 and/or 25, or a variant of said fragment.
- 35

14. The polypeptide of claim 2, wherein the polypeptide is a fragment of SEQ ID NO:5 of less than 727 amino-acid residues in length, e.g. less than 400, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:15,16 and/or 27, or a variant of said fragment.
15. The polypeptide of claim 2, wherein the polypeptide is a fragment of SEQ ID NO:6 of less than 748 amino-acid residues in length, e.g. less than 400, such as less than 200, preferably less than 100, such as less than 75, e.g. less than 50, such as less than 25 amino-acid residues in length comprising one or more residues of the amino-acid sequences set forth in SEQ ID NO:34 or a variant of said fragment.
16. The composition of claim 1, wherein the one or more polypeptide(s) is a (are) polypeptide(s) as defined in any of claims 2-15.
17. A polynucleotide encoding a polypeptide as defined in any of claims 2-15.
18. An expression vector comprising a polynucleotide as defined in the preceding claim.
19. A host cell transformed or transfected with a polynucleotide as defined in claim 17 and/or an expression vector as defined in claim 18.
20. A pharmaceutical composition comprising a polypeptide as defined in any of claims 2-15 or a polynucleotide as defined in claim 17 and a pharmaceutically-acceptable carrier.
21. Use of a polypeptide as defined in any of claims 2-15, a polynucleotide as defined in claim 17 or a composition as defined in any of claims 1,16 or 20 for the preparation of a medicament.
22. Use of a polypeptide as defined in any of claims 2-15, a polynucleotide as defined in claim 17 or a composition as defined in any of claims 1,16 or 20 for

the manufacture of a medicament for the immunisation of a mammal against fungal infections.

23. The use of claim 22, wherein said mammal is a human being.

24. A method for raising specific antibodies to a polypeptide selected from the group of polypeptides set forth in SEQ ID NO:1,2,3 and 6 in a non-human mammal comprising the steps of

- a. providing a polypeptide selected from the group of Cssl (SEQ ID NO:1), hydrophobin (SEQ ID NO:2), GAPDH (SEQ ID NO:3), and catalase A (SEQ ID NO:6),
- b. introducing a composition comprising said polypeptide into said animal,
- c. raising antibodies in said animal, and
- d. isolating and optionally purifying the antibodies.

25. A method for raising specific antibodies to a polypeptide as defined in any of claims 2-15 in a non-human mammal comprising the steps of

- a. providing a polypeptide as defined in any of claim 2-15,
- b. introducing a composition comprising said polypeptide into said animal,
- c. raising antibodies in said animal, and
- d. isolating and optionally purifying the antibodies.

26. The method of claim 24 or 25, wherein the raising of antibodies is done in a transgenic animal which can produce human antibodies.

27. The method of any of claims 24-26, wherein the polypeptide that is provided is Cssl (SEQ ID NO:1) or a fragment thereof, or a variant of said polypeptide.

28. The method of any of claims 24-26, wherein the polypeptide that is provided is hydrophobin (SEQ ID NO:2) or a fragment thereof, or a variant of said polypeptide.

29. The method of any of claims 24-26, wherein the polypeptide that is provided is GAPDH-B (SEQ ID NO:3) or a fragment thereof, or a variant of said polypeptide.

30. The method of any of claims 24-26, wherein the polypeptide that is provided is catalase A (SEQ ID NO:6) or a fragment thereof, or a variant of said polypeptide.
- 5 31. An antibody capable of specifically recognising and binding a polypeptide selected from the group of Cssl (SEQ ID NO:1), hydrophobin (SEQ ID NO:2), GAPDH-B (SEQ ID NO:3), catalase A (SEQ ID NO:6), and the polypeptides as defined in any of claims 2-15.
- 10 32. The antibody of claim 31, wherein the antibody specifically recognises and binds Cssl (SEQ ID NO:1), hydrophobin (SEQ ID NO:2) or GAPDH-B (SEQ ID NO:3).
33. The antibody of claim 32, wherein the antibody specifically recognises and binds Cssl (SEQ ID NO:1).
- 15 34. The antibody of any of claims 31-33, wherein the antibody is polyclonal.
35. The antibody of any of claims 31-33, wherein the antibody is monoclonal.
- 20 36. The antibody of the preceding claim, wherein the antibody is a human or humanised antibody.
37. The antibody of the preceding claim, wherein the antibody is a human antibody.
- 25 38. A pharmaceutical composition comprising an antibody as defined in any of claims 31-37 and a pharmaceutically-acceptable carrier.
39. Use of an antibody as defined in any of claims 31-37 or a composition as defined in claim 38 for the manufacture of a medicament.
- 30 40. Use of an antibody as defined in any of claims 31-37 or a composition as defined in claim 38 for the manufacture of a medicament for the treatment or prevention of fungal infections.
- 35 41. A method for identifying a binding partner of a polypeptide as defined in any of claims 2-15 and/or a polypeptide selected from the group of Cssl (SEQ ID

NO:1), hydrophobin (SEQ ID NO:2), GAPDH-B (SEQ ID NO:3), catalase B (SEQ ID NO:5), and catalase A (SEQ ID NO:6), comprising the steps of

- 5 a. providing a polypeptide as defined in any of claims 2-15 or a polypeptide selected from the group of Cssl (SEQ ID NO:1), hydrophobin (SEQ ID NO:2), GAPDH-B (SEQ ID NO:3), catalase B (SEQ ID NO:5), and catalase A (SEQ ID NO:6),
- b. contacting said polypeptide with a putative binding partner, and
- c. determining whether said putative binding partner is capable of binding to said polypeptide.

10

42. The method of claim 41, wherein the polypeptide that is provided is Cssl (SEQ ID NO:1) or a fragment thereof, or a variant of said polypeptide.

15

43. The method of claim 41, wherein the polypeptide that is provided is hydrophobin (SEQ ID NO:2) or a fragment thereof, or a variant of said polypeptide.

44. The method of claim 41, wherein the polypeptide that is provided is GAPDH-B (SEQ ID NO:3) or a fragment thereof, or a variant of said polypeptide.

20

45. The method of claim 41, wherein the polypeptide that is provided is catalase B (SEQ ID NO:5) or a fragment thereof, or a variant of said polypeptide.

25

46. The method of claim 41, wherein the polypeptide that is provided is catalase A (SEQ ID NO:6) or a fragment thereof, or a variant of said polypeptide

47. The method of any of claims 41-46, wherein the putative binding partner is a host-derived molecule.

30

48. The method of any of claims 41-47, wherein said method is repeated for a plurality of putative binding partners.

35

49. A method for identifying a compound with antifungal activity comprising the steps of

- a. providing a sensitised cell which has a reduced level of a polypeptide selected from the group of SEQ ID NOs:1,2,3,5 and 6, and

- b. determining the sensitivity of said cell to a putative antifungal compound, for instance by a growth assay.
- 5 50. The method of claim 49, wherein said method is repeated for a plurality of putative antifungal compounds.
- 10 51. A method for finding an inhibitor of an extracellular *Aspergillus* polypeptide comprising the steps of
- a. providing two cells which differ in the level of a polypeptide selected from the group of Cssl (SEQ ID NO:1), GAPDH (SEQ ID NO:3), and catalase A (SEQ ID NO:6),
- b. determining the sensitivity of said cells to a putative inhibitor, for instance by a growth assay, and
- 15 c. determining whether said two cells are differently affected by the presence of said putative inhibitor.
52. The method of claim 51, wherein the two cells differ in the copy number of said polypeptide.
- 20 53. The method of claim 51, wherein the two cells differ in the activity of said polypeptide.
54. The method of any of claims 51-53, wherein said method is repeated for a plurality of putative inhibitors.
- 25 55. A method of diagnosing *Aspergillus* infection comprising the steps of
- a. providing a sample from an individual,
- b. contacting said sample with an indicator moiety specific for a polypeptide as defined in any of claims 2-15, or specific for a polypeptide selected from the group of Cssl (SEQ ID NO:1), hydrophobin (SEQ ID NO:2), GAPDH-B (SEQ ID NO:3), and catalase A (SEQ ID NO:6), and
- 30 c. determining whether a signal has been generated by the indicator moiety.
- 35 56. The method of the preceding claim, wherein said indicator moiety is or comprises an antibody, such as an antibody as defined in any of claims 31-37.

10 JUNI 2003

Modtaget

A

MLASFQFCILPRTYRTLLCSAGAGPLLI IQFVTVASALALAPTAVVARQGAAAFVTVNSIDVCPKKVAQEIIINPGPKVVT
TPYTCDQVKLGHLDVSYNFDIEPLTKDTFPYCKALKVFDNEGCLGFPTLWIPLESPLDKCIPHYFSDEVKSISFQL
DCREDAPVKKEPYGPKGAEQSAPOAEHSTKQDAQQSGHQGEVQNSPKQEARQGSRPAAAPKQEQEAEQASEAAPEKK
ASNPA DSLGLGELTKVLGFR

B

VRFPVPDDITVKQATEKCGDQAQLSCCNKATYAGDVTIDIDEGILAGTLKKNLIGGGSGTEGLGLFNQC SKLDLQSPIIGIP
IQDLVNQKCKQNIACCCNSPSDAVRFP

C

MATPKVGINGFGRIGRIVGLNSLSHGVDVVAVNDPFI EVHYAAYMLKYDTTHGQFKGTIETYDQGLIVNGKKIRFYAEKD
PSQIPWSETGAAYIVESTGVFTTKEKASAHKGGAKKVIISAPSADAPMFVMGVNNTTYTSDIQVLSNASCTTNCLAPLA
KVINDKFGIVEGLMTTVHSYTATQKVVDAPSNKDWRGGRRTAAQNIIPSSTGAAKAVGKVIPSLNGKLTGMAMRVPTSNVS
VVDLTCRLEKGASYDEIKQAIIKAASEEGELKNILGYTEDDVVSSDLNGDERSSIFDAKAGISLNP NFVKLVAWYDNEW

D

MPISKIHARSVYDSRGNPTVEVDVATETGLHRAIVPSGASTGQHEAHEL RDGDKTQWGGKGVLKAVKNVNETIGPALIKE
NIDVKDQSKVDEFLNKL DGTANKSNL GANAILGVSLAVAKAGAAEKGVPLYAHI SLAGTKKPYVLPVFPQNVNLNGGSHA
GGRLAQEFMIVPDSAPSFSSEALRQGA EYQKLKALAKKKYQSAGNVGDEGGVAPDIQTAEALDLITEAIEQAGYTGK
IKIAMDVASSEFYKADVKKYDLDFKNPESDPSKWLTYEQLADLYKSLAAKYP IVSIEDPFAEDDWEAWSYFYKTSDFQIV
GDDLTVTNPGRIKKAIELKSCNALLKVNQIGTLTESIQAAKDSYADNWGMVSHRSGETEDVTIADI AVLGRSGQIKTG
APCRSERLAKLNQILRIEEELGENTVYAGSKFRTAVNL

E

MRLTFIPSLIGVANAVCPYMTGELNRRDEISDGDAAAATEEFLSQYYLNDNDAFMTSDVGGPIEDQNSLSAGERGPTLLE
DFIFRQKIQRFDHERVPERAVHARGAGAHGVFTSYGDFS NITAASFLAKEGKQTPVFVRVSTVAGSRCSSDLARDVHGFA
TRFYTDEGNFDIVGN NIPVFFIQDAILFPDLIHAVKPRGDNEI PQAATAHDSAWDFFSQQPSTMHTLLWAMSGHGIPRSF
RHVDGFGVHTFRFVTDGASKLVKFHWKSLQKGASMWEEAQQTSGKNPDMRQDLHDAIEAGRYPEWELGVQIMDEEDQ
LRFGLDLLDPTKIVPEEFVPITKLGKMLNRNPRNYFAETE QVMFQPGHIVRGVDFTEDPLLQGR LFSYLD TQLNRHGGP
NFEQLPINQPRVPVHNNNRD GAGOMFIPLNPHAYSPKTSVNGSPKQANQTVGDGFFTA PGRTTSGKLVRVAVSSSFEDVWS
QPRLFYNSLVPAEKQFVIDAIRFENANVKS PVVKNNV I IQLNRIDNDLARRVARAIGVAEPEPDPTFYHNNKTADVGTFC
TKLKL DGLKVGVLG SVQH PGSGASTLRDLKDDGV DVVLVAERLADGV DQTYSTSDAIQF DAVVVAAGAESLFAASS
FTGGSANSASGASSLYPTGRPLQILIDGFRFGKTVGALGSGTAALRNAGIATSRDGVYVAQSVTDDFANDLKEGLRTFKF
LDRFPVDH

F

MATKIAGGLHRAQEV LQNTSSKSKKLVDLERDTADAHTQQPLT TDHGVRVSNTDQWLRVTNDRRTGPSLLEDQIAREKIH
RFDHERIPERVVHARGTGA FGNFKLKESIEDLTYAGVLT DTSRNTPVFVRVSTVQGSRG SADTVRDVRGFAVKFYTDEGN
WDIVGN NIPVFFIQDAVKFPDFVHAVKPEPHNEVPQAQTAHNNFWDFVYLHPEATHMFMWAMSDRAIPRSYRMMQGFV N
TFALVNKEGKRHFVKFWI PHLGVHSLVWDEALKLGGQDPDFHRKDLMEAI DNKAYPKWDFAIQVIPEEKQDDFEFDILD
ATKIWPENLVPLRVIGELELN RNVD EFPQTEQVAFCTSHIVPGIDFTDDPLLQGRNFSYFDTQISRLGINWHEELPINRP
VCPVLNHN RDGQMRHRITQGT VNYWPNRFEAVPPTG TKSGVGGGFTTYPQ RVEGIKNRALNDK FREHNNQAQLFYNSMS
EHEKLMHKKAFS FELDHCD DPTVYERLAGHRLAEIDLELAQKVAEMVGAPIPAKALKQNHGRRAPHL SQTEFI PKNPTIA
SRRIAIIGDGYDPVASTGLKTA IKAASALPFIIGTKRSAIYATEDKTSKGIIPDHHYD GQRSTMF DATFIPGGPHVAT
LRONGQIKYWISETFGHLKALGATGEAVDLVKETLSGTLHVQVASSQSPEPVEWYGVVTTAGGKQKPESFKESVQILKGAT
DFVGKFFYQISQHRNYQRELDGLASTIAF

Figure 1. The predicted protein sequences of Cssl (A), hydrophobin (B), GAPDH-B (C), enolase (D), catalase B (E) and catalase A(F).

Patent- og
Varemærkestyrelsen

1 0 JUNI 2003

Modtaget




Figure 2. The predicted antigenicity indices of Cssl (A) and hydrophobin (B) residues.

10 JUNI 2003

Modtaget

```

Afa  [REDACTED] F F F F D E E [REDACTED] D P K [REDACTED] R E E E S Q E G S T I Q R V K
Afb  [REDACTED] G L [REDACTED] G V D [REDACTED] E V R [REDACTED] T Q K G T E T Y D G I V N K I R
Afc  [REDACTED] I [REDACTED] C N L A A N R P D [REDACTED] T H T C T T E D D L I H L I R [REDACTED] X M N L P T S P I H A L S D T L L S I N G H Q I A L T S

Afa  [REDACTED] A R [REDACTED] E [REDACTED] V D [REDACTED] K [REDACTED] R [REDACTED] V [REDACTED] Y [REDACTED] E E K D G T A D [REDACTED] V [REDACTED] A [REDACTED] V
Afb  [REDACTED] S Q [REDACTED] S [REDACTED] A [REDACTED] V [REDACTED] K E [REDACTED] S [REDACTED] K [REDACTED] N T T S I Q [REDACTED] L [REDACTED] A [REDACTED] V
Afc  E R T L Q N L D A A L E E V C K K H A Q L E V T H R [REDACTED] T F [REDACTED] S D E [REDACTED] E A R R X I C [REDACTED] V T V L

Afa  [REDACTED] E E F [REDACTED] A I [REDACTED] L [REDACTED] S [REDACTED] A E [REDACTED] E C [REDACTED] D
Afb  [REDACTED] D [REDACTED] I [REDACTED] S [REDACTED] A A N [REDACTED] T A C [REDACTED] S N E [REDACTED] D
Afc  L Q G Q I A Q F L [REDACTED] A R S S L Y R N R L S V F D [REDACTED] T T [REDACTED] I A T L A S [REDACTED] V S T [REDACTED] F

Afa  [REDACTED] I S T E V A E [REDACTED] A H E [REDACTED]
Afb  V V [REDACTED] L G [REDACTED] D A K O [REDACTED] A S E E [REDACTED] N I G Y T D D V [REDACTED] L N D E R S [REDACTED] F K G S [REDACTED] N [REDACTED] L V [REDACTED] D N E W
Afc  M [REDACTED] V S T [REDACTED] P T L A V L [REDACTED] V F R R [REDACTED] K [REDACTED] A V A V S E E L [REDACTED] Y L N P H A I [REDACTED] P C E [REDACTED] T S O F F I M

```

Figure 3. Alignment of the predicted protein sequences for GAPDH-A (Afa), GAPDH-B (Afb) and GAPDH-C3 (Afc). Residues that are identical are presented on a dark background. Peptides of GAPDH-B that have been identified by MS have been underlined.

Table 1. Identification of peptides in AfC fractions.

Protein extract	Cssl (AnrP440134)	Hydrophobin (AnrP57221)	GAPDH (AnrP539502)	Enolase (AnrP7789)	Catalase
Diffusate	KVAQEIIINPGPK	FPVPDDITVK ATYAGDVTDIDEGILAGTLK	AGISLNPNFVK TAAQNIIIPSSSTGAAG NILGYTEDDVVSSDLNGDER	NVNETIGPALIK VNQIGTLTESIQAAK TSDFQIVGDDLTVTNPGR WLTYEQLADLYK	Not detected
Cell surface exposed	VAQEIIINPGPK	FPVPDDITVK ATYAGDVTDIDEGILAGTLK	Not detected	Not detected	FGFDLLDPTK (Catalase B peptide AnrP977704)
Cell wall	KVAQEIIINPGPK VAQEIIINPGPK SISFQLDCR EGAEQSAPOAEHSTK VVTTPYTCQVK	FPVPDDITVK 3-12 ATYAGDVTDIDEGILAGTLK 30-50	AGISLNPNFVK TAAQNIIIPSSSTGAAG NILGYTEDDVVSSDLNGDER VPTSNVSVVDLTCR YDTHGQFK GTIETYDQGLIVNGK	Not detected	TGPSLLEDQIAR (Catalase A peptide AnrP145557)
Peptides used for Ab production	KVAQEIIINPGPKVVTT KEGAEQSAPOAEHSTK	FPVPDDITVKQATEKCGD ATYAGDVTDIDEGIL	TEDDVVSSDLNGDERS FKGTIETYDQGLIVNGKK	KNVNETIGPALIKENID TSDFQIVGDDLTVTNPGR	DEEDQLRFGFDLLDPTKIVP RIDNDLARRVARAIGV

Table 2. Biochemical characteristics of Cssl.

	Complete	N-terminus	C-terminus
MW	28179.92	13960.38	14236.54
Residues	260	130	130
Strongly Basic (+) Amino Acids (K, R)	25	10	15
Strongly Acidic (-) Amino Acids (D, E)	33	9	24
Hydrophobic Amino Acids (A, I, L, F, W, V)	89	55	34
Polar Amino Acids (N, C, Q, S, T, Y)	70	36	34
Isoelectric Point	5.081	7.626	4.760
Charge at pH 7.0	-7.634	0.892	-8.617

10 JUNI 2003

Modtaget

SEQ ID NO: 1 (CssI, 260 aa)

MLASFQFCILPRTYRTLLCSAGAGPLLIQFVTVASALALAPTAVVARQGAAAFVTVNSIDVCPKKVAQEIIINPGPKVVT
TPYTCDQVKLGHLGHDVSYNFDIEPLTKDTFFPYCKALKVFDNEGCLGFPTLWIPILESPLDKCIPEHYFSDEVKSISFQL
DCREDAPVKKEPYGPKGAEQSAQAHEHSTKQDAQQGSHQGQEVQNSPKQEARQGSRAEAPKQEQEAEQASEAAPEKK
ASNPADSLGLGELTKVLGFR

SEQ ID NO: 2 (Hydrophobin, 107 aa)

VRFPVDDITVKQATEKCGDQAQLSCCNKATYAGDVTDDIDEGILAGTLKLNLIIGGSGTEGLGLFNQCSKLDLQSPIIGIP
IQDLVNQKCKQNIACQNSPSDAVRFP

SEQ ID NO: 3 (GAPDH-B, 318 aa)

MATPKVGINGFGRIGRIVGLNSLSHGVDVVAVNDPFI EVHYAAYMLKYDTTHGQFKGTIETYDQGLIVNGKKIRFYAEKD
PSQIPWSETGAAYIVESTGVFTTKEKASAHKGGAKKVIISAPSADAPMFVMGVNNTTYTSDIQVLSNASCTTNCLAPLA
KVINDKFGIVEGLMTTVHSYTATQKVVDAPSNKDWRGGRATAQNIIPSSGTAAKAVGKVI PSLNGKLTGMAMRVPTSNVS
VVDLTCRLEKGASYDEIKQAIIKAASEEGLKNILGYTEDDVSSDLNGDERSSIFDAKAGISLNPNFVKLVAWYDNEW

SEQ ID NO: 4 (enolase, 438 aa)

MPISKIHARSVYDSRGNPTVEVDVATETGLHRAIVPSGASTGQHEAHEL RDGDKTQWGGKGV LKAVKNVNETIGPALIKE
NIDVKDQSKVDEFLNKL DGTANKSNLGNAILGVSLAVAKAGAAEKGVPLYAHISDLAGTKKPYVLPVPFQNVNLNGGSHA
GGRLAQEFMIVPDSAPSFSEALRQGAEVYQKLKALAKKKYQGSAGNVGDEGGVAPDIQTAEALDLITEAIEQAGYTGK
IKIAMDVASSEFYKADVKKYDLDFKNPESDPSKWLTYEQ LADLYKSLA AKYPIVSIEDPFAEDDWEAWSYFYKTSDFQIV
GDDLTVTNPGRIKKAIELKSCNALLKVNQIGTLTESIQA AKDSYADNWGMVSHRSGETEDVTIADIAVGLRSGQIKTG
APCRSERLAKLNQILRIEELGENTVYAGSKFRTAVNL

SEQ ID NO: 5 (catalase B, 728 aa)

MRLTFIPSLIGVANAVCPYMTGELNRRDEISDGDAAAATEEFLSQYYLNDNDAFMTSDVGGPIEDQNSLSAGERGPTLLE
DFIFRQKIQRFDHERVPERAVHARGAGAHGVFTSYGDFSNI TAASFLAKEGKQTPVVFVRFSTVAGSRGSSDLARDVHGFA
TRFYTDDEGNFDIVGNNIPVFFIQDAILFPDLIHAVKPRGDNEIPQAATAHDSAWDFFSQQPSTMH TLWAMSGHGIPRSF
RHVDGFGVHTFRFVTDDGASKLVKFHWKSLQGKASMVWEEAQQTSGKNPDMRQDLHDAIEAGRYPEWELGVQIMDEEDQ
LRFGFDLLDPTKIVPEEFVPITKLGKMQLNRPNYFAETE QVMFQPGHIVRGVDFTEDP LLQGR LFSYLD TQLNRHGGP
NFEQLPINQPRVPVHNNNRDAGQMFIPLNPHAYS PKTSVNGSPKQANQTVGDGFFTAPGR TTSGLVRAVSSSFEDVWS
QPRLFYNSLVPAEKQFVIDAIRFENANVKSPVVKNNV IQLNRIDNDLARRVARAIGVAEPEPDPTFYHNNKTADVGTFG
TKLKKLDGLKVGVLGSGVQHGPSVEGASTLRDR LKDDGVDVVLVAERLADGVDQTYSTSDAIQFDVAVVAAGAESLFAASS
FTGGSANSASGASSLYPTGRPLQILIDGFRFGKTVGALGSGTAALRNAGIATSRDGVYVAQSVTDDFANDLKEGLRTFKF
LDRFPVDH

SEQ ID NO: 6 (catalase A, 749 aa)

MATKIAGGLHRAQEV LQNTSSKSKKLVDLERDTADAHTQQPLT TDHGVRVSN TDQWLRVTNDRRTGPSLLEDQIAREKIH
RFDHERIPERVHARGTGAFGNFKLKESIEDLTYAGVLT DTSRNTPVFVRFSTVQGSRGSA DTVRDVRGFAVKFYTDEGN
WDIVGNNIPVFFIQDAVKFPDFVHAVKPEPHNEVPQAQTAHNNFWDFVYLHPEATHMFMWAMSDRAIPRSYRMMQGFVGN
TFALVNKEGKRHFVKFHWI PHLGVHSLVWDEALKGGQDPDFHRKDLMEAI DNKAYPKWDFAIQVIPEEKQDDFEFDILD
ATKIWPENLVPLRVIGELELN RVDEFFPQTEQVAFCTSHIVPGIDFTDDP LLQGRNFSYFDTQISRLGINWEELPINRP
VCPVLNHN RDGQMRHRTQGT VNYWPNRFEAVPPTG TKGSGVGGGFTTYPQRVEGIKNRALNDK FREHHNQAQLFYNSMS
EHEKLMKKAFS FELDHCDPTVYERLAGHRLAEIDLELAQKVAEMVGAPIPAKALKQNHGRRAPHL SQTEFIPKNPTIA
SRRIAIIGDGYDPVASTGLKTAIKAASALPFIIGTKRSAIYATEDKTSKGIIPDHHDYDQGRSTMF DATFI PGGPHVAT
LRQNGQIKYWISETFGHLKALGATGEAVDLVKETLSGTLHVQVASSQSPEPVEWYGVV TAGGKQKPESFKESVQILKGAT
DFVGKFFYQISQHRNYQRELDGLASTIAF

SEQ ID NO: 7 : KVAQEIIINPGPKVVT (a CssI fragment)

SEQ ID NO: 8 : KEGAEQSAQAHEHSTK (a CssI fragment)

SEQ ID NO: 9 : PVPDDITVKQATEKCGD (a hydrophobin fragment)

SEQ ID NO:10 : ATYAGDVTIDIEGIL (a hydrophobin fragment)
 SEQ ID NO:11 : TEDDVVSSDLNGDERS (a GAPDH-B fragment)
 SEQ ID NO:12 : FKGTIETYDQGLIVNGKK (a GAPDH-B fragment)
 SEQ ID NO:13 : KVNNETIGPALIKENID (an enolase fragment)
 SEQ ID NO:14 : TSDFQIVGDDLTVTNPGR (an enolase fragment)
 SEQ ID NO:15 : DEEDQLRFGFDLLDPTKIVP (a catalase B fragment)
 SEQ ID NO:16 : RIDNDLARRVARAIGV (a catalase B fragment)
 SEQ ID NO:17 : KVAQEIIINPGPK (a Cssi fragment)
 SEQ ID NO:18 : FPVPDDITVK (a hydrophobin fragment)
 SEQ ID NO:19 : ATYAGDVTIDIEGILAGTLK (a hydrophobin fragment)
 SEQ ID NO:20 : AGISLNPNEFVK (a GAPDH-B fragment)
 SEQ ID NO:21 : TAAQNIIPSSTGAAK (a GAPDH-B fragment)
 SEQ ID NO:22 : NILGYTEDDVVSSDLNGDER (a GAPDH-B fragment)
 SEQ ID NO:23 : NVNETIGPALIK (an enolase fragment)
 SEQ ID NO:24 : VNQIGTLTESIQAAK (an enolase fragment)
 SEQ ID NO:25 : WLTYEQLADLYK (an enolase fragment)
 SEQ ID NO:26 : VAQEIIINPGPK (a Cssi fragment)
 SEQ ID NO:27 : FGFDLLDPTK (a catalase B fragment)
 SEQ ID NO:28 : SISFQLDCR (a Cssi fragment)
 SEQ ID NO:29 : EGAEQSAPQAEHSTK (a Cssi fragment)
 SEQ ID NO:30 : VVTTPYTCDQVK (a Cssi fragment)
 SEQ ID NO:31 : VPTSNVSVVDLTCR (a GAPDH-B fragment)
 SEQ ID NO:32 : YDTHGQFK (a GAPDH-B fragment)
 SEQ ID NO:33 : GTIETYDQGLIVNGK (a GAPDH-B fragment)
 SEQ ID NO:34 : TGPSLLEDQIAR (a catalase A fragment)
 SEQ ID NO:35 :

1SNASCTTNCLAPLAKVINDKFGIVEGLMTTVHSYTATQKVVDAPSNKDWRGGRATAAQNIIPSSTGAAKAVGKVIPSLNGK
 2LTGMAMRVPTSNVSVVDLTCRLEKGASYDEIKQAIKAASEEGELKNILGYTEDDVVSSDLNGDERSSIFDAKAGISLNP
 3FVKLVAWYDNEW